# Freetown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 9 | 11.5 | 78.4 | (35.8-148.8) |  | Male | 4 | 7.3 | nc | (nc-nc) |
| Female | 1 | 3.1 | nc | (nc-nc) |  | Female | 4 | 4.7 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 2.1 | nc | (nc-nc) |  | Male | 1 | 2.4 | nc | (nc-nc) |
| Female | 1 | 1.5 | nc | (nc-nc) |  | Female | 3 | 1.5 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 4 | 6.5 | nc | (nc-nc) |
| Female | 48 | 39.2 | 122.4 | (90.3-162.3) |  | Female | 4 | 4.4 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 7 | 5.5 | 126.3 | (50.6-260.3) |
| Female | 2 | 1.3 | nc | (nc-nc) |  | Female | 2 | 2.0 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 7 | 12.2 | 57.4 | (23.0-118.2) |  |  |  |  |  |  |
| Female | 4 | 8.9 | nc | (nc-nc) |  | Female | 2 | 3.3 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 2.9 | nc | (nc-nc) |  | Male | 0 | 4.2 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 6 | 3.2 | 188.8 | (69.0-411.0) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.8 | nc | (nc-nc) |  | Male | 38 | 34.4 | 110.5 | (78.2-151.7) |
| Female | 0 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 4 | 6.7 | nc | (nc-nc) |  | Male | 2 | 2.7 | nc | (nc-nc) |
| Female | 2 | 3.0 | nc | (nc-nc) |  | Female | 1 | 1.3 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 1.6 | nc | (nc-nc) |  | Male | 0 | 1.4 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 4.6 | nc | (nc-nc) |  | Male | 4 | 3.0 | nc | (nc-nc) |
| Female | 2 | 2.5 | nc | (nc-nc) |  | Female | 9 | 7.5 | 119.8 | (54.7-227.4) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 4.0 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 1.1 | nc | (nc-nc) |  | Female | 10 | 9.0 | 110.9 | (53.1-204.0) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 16 | 19.6 | 81.5 | (46.6-132.4) |  | Male | 117 | 145.4 | 80.4 | (66.5-96.4) |
| Female | 23 | 17.2 | 133.7 | (84.7-200.7) |  | Female | 147 | 125.7 | 116.9 | (98.8-137.4) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

112

# Gardner

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 13 | 23.4 | 55.5 | (29.5-94.9) |  | Male | 4 | 14.8 | nc | (nc-nc) |
| Female | 11 | 8.6 | 127.3 | (63.5-227.8) |  | Female | 11 | 11.3 | 97.0 | (48.3-173.5) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 5 | 4.4 | 114.9 | (37.0-268.1) |  | Male | 3 | 4.8 | nc | (nc-nc) |
| Female | 5 | 3.7 | 135.4 | (43.6-316.0) |  | Female | 2 | 4.0 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.8 | nc | (nc-nc) |  | Male | 11 | 13.2 | 83.4 | (41.6-149.2) |
| Female | 59 | 89.7 | 65.8 | (50.1-84.9) |  | Female | 9 | 11.6 | 77.7 | (35.5-147.6) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 11 | 10.6 | 103.7 | (51.7-185.6) |
| Female | 0 | 2.8 | nc | (nc-nc) |  | Female | 5 | 5.0 | 99.7 | (32.1-232.6) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 30 | 24.3 | 123.3 | (83.1-176.0) |  |  |  |  |  |  |
| Female | 25 | 24.2 | 103.1 | (66.7-152.2) |  | Female | 9 | 7.9 | 114.1 | (52.1-216.6) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 11 | 5.8 | 190.9 | (95.2-341.6) |  | Male | 8 | 8.5 | 93.7 | (40.4-184.7) |
| Female | 0 | 1.7 | nc | (nc-nc) |  | Female | 5 | 9.0 | 55.6 | (17.9-129.7) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 1.7 | nc | (nc-nc) |  | Male | 43 | 65.7 | 65.5 | (47.4-88.2) |
| Female | 3 | 1.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 15 | 13.0 | 115.5 | (64.6-190.5) |  | Male | 2 | 5.4 | nc | (nc-nc) |
| Female | 9 | 7.4 | 122.3 | (55.8-232.1) |  | Female | 6 | 3.4 | 175.5 | (64.1-382.0) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 3 | 3.3 | nc | (nc-nc) |  | Male | 3 | 3.3 | nc | (nc-nc) |
| Female | 2 | 1.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 13 | 9.3 | 139.3 | (74.1-238.2) |  | Male | 2 | 5.9 | nc | (nc-nc) |
| Female | 12 | 6.9 | 174.2 | (89.9-304.3) |  | Female | 11 | 15.9 | 69.4 | (34.6-124.2) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 11 | 7.9 | 139.3 | (69.4-249.3) |  |  |  |  |  |  |
| Female | 4 | 2.9 | nc | (nc-nc) |  | Female | 21 | 20.5 | 102.3 | (63.3-156.4) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 60 | 40.2 | 149.4 | (114.0-192.3) |  | Male | 269 | 290.2 | 92.7 | (81.9-104.5) |
| Female | 53 | 44.3 | 119.6 | (89.6-156.4) |  | Female | 290 | 308.7 | 93.9 | (83.4-105.4) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

113

# Georgetown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 6 | 8.7 | 69.0 | (25.2-150.3) |  | Male | 6 | 5.8 | 103.6 | (37.8-225.5) |
| Female | 2 | 2.9 | nc | (nc-nc) |  | Female | 4 | 4.6 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 1.8 | nc | (nc-nc) |  | Male | 0 | 1.9 | nc | (nc-nc) |
| Female | 1 | 1.5 | nc | (nc-nc) |  | Female | 2 | 1.5 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 7 | 5.1 | 136.8 | (54.8-281.8) |
| Female | 31 | 38.9 | 79.6 | (54.1-113.0) |  | Female | 2 | 4.3 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 4.5 | nc | (nc-nc) |
| Female | 0 | 1.3 | nc | (nc-nc) |  | Female | 2 | 2.0 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 6 | 9.6 | 62.6 | (22.8-136.2) |  |  |  |  |  |  |
| Female | 6 | 8.6 | 69.5 | (25.4-151.3) |  | Female | 0 | 3.2 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 2.3 | nc | (nc-nc) |  | Male | 5 | 3.3 | 151.7 | (48.9-354.0) |
| Female | 1 | 0.6 | nc | (nc-nc) |  | Female | 3 | 3.0 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.7 | nc | (nc-nc) |  | Male | 32 | 28.3 | 113.2 | (77.4-159.8) |
| Female | 0 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 4 | 5.5 | nc | (nc-nc) |  | Male | 2 | 2.1 | nc | (nc-nc) |
| Female | 2 | 3.0 | nc | (nc-nc) |  | Female | 0 | 1.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 1.3 | nc | (nc-nc) |  | Male | 2 | 1.3 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 2 | 3.6 | nc | (nc-nc) |  | Male | 3 | 2.5 | nc | (nc-nc) |
| Female | 2 | 2.5 | nc | (nc-nc) |  | Female | 5 | 7.3 | 68.5 | (22.1-160.0) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 3.2 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 1.0 | nc | (nc-nc) |  | Female | 10 | 9.0 | 110.9 | (53.1-203.9) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 7 | 15.7 | 44.7 | (17.9-92.0) |  | Male | 98 | 116.1 | 84.4 | (68.5-102.9) |
| Female | 11 | 16.2 | 68.0 | (33.9-121.6) |  | Female | 97 | 122.4 | 79.3 | (64.3-96.7) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

114

# Gill

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 2 | 2.2 | nc | (nc-nc) |  | Male | 0 | 1.4 | nc | (nc-nc) |
| Female | 1 | 0.6 | nc | (nc-nc) |  | Female | 0 | 0.9 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 1 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 1 | 1.2 | nc | (nc-nc) |
| Female | 6 | 7.6 | 78.5 | (28.7-170.8) |  | Female | 1 | 0.9 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 1.1 | nc | (nc-nc) |
| Female | 1 | 0.2 | nc | (nc-nc) |  | Female | 1 | 0.4 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 1 | 2.3 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 1.7 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 0 | 0.8 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 1 | 0.6 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.2 | nc | (nc-nc) |  | Male | 4 | 7.0 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 1.3 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 1 | 0.6 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 0 | 1.4 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 2 | 1.9 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 10 | 3.9 | 256.8 | (123.0-472.4) |  | Male | 23 | 28.5 | 80.7 | (51.1-121.0) |
| Female | 4 | 3.3 | nc | (nc-nc) |  | Female | 22 | 24.6 | 89.4 | (56.0-135.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

115

# Gloucester

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 43 | 40.0 | 107.6 | (77.9-144.9) |  | Male | 26 | 24.8 | 104.9 | (68.5-153.7) |
| Female | 27 | 14.8 | 182.5 | (120.2-265.5) |  | Female | 28 | 19.5 | 143.9 | (95.6-207.9) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 3 | 6.9 | nc | (nc-nc) |  | Male | 9 | 8.2 | 110.2 | (50.3-209.2) |
| Female | 4 | 6.3 | nc | (nc-nc) |  | Female | 3 | 6.9 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 2 | 1.4 | nc | (nc-nc) |  | Male | 26 | 22.0 | 118.4 | (77.3-173.5) |
| Female | 175 | 161.3 | 108.5 | (93.0-125.8) |  | Female | 24 | 20.0 | 120.0 | (76.9-178.6) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 27 | 18.9 | 142.9 | (94.1-207.8) |
| Female | 4 | 4.8 | nc | (nc-nc) |  | Female | 9 | 8.9 | 101.3 | (46.2-192.4) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 37 | 40.4 | 91.6 | (64.5-126.3) |  |  |  |  |  |  |
| Female | 51 | 41.4 | 123.3 | (91.8-162.1) |  | Female | 22 | 13.9 | 158.6 | (99.3-240.1) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 12 | 10.3 | 116.7 | (60.2-203.9) |  | Male | 27 | 14.8 | 182.0 | (119.9-264.8) |
| Female | 1 | 2.9 | nc | (nc-nc) |  | Female | 12 | 15.5 | 77.6 | (40.1-135.6) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 4 | 2.4 | nc | (nc-nc) |  | Male | 115 | 128.6 | 89.4 | (73.8-107.3) |
| Female | 3 | 2.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 27 | 22.6 | 119.5 | (78.7-173.9) |  | Male | 9 | 9.3 | 97.2 | (44.3-184.4) |
| Female | 15 | 13.0 | 115.6 | (64.7-190.7) |  | Female | 2 | 5.8 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 8 | 6.0 | 134.2 | (57.8-264.4) |  | Male | 5 | 3.8 | 131.6 | (42.4-307.0) |
| Female | 3 | 1.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 20 | 15.3 | 130.3 | (79.6-201.2) |  | Male | 11 | 9.0 | 122.2 | (60.9-218.6) |
| Female | 13 | 11.5 | 113.0 | (60.1-193.3) |  | Female | 32 | 26.7 | 119.7 | (81.8-168.9) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 9 | 14.5 | 62.0 | (28.3-117.8) |  |  |  |  |  |  |
| Female | 5 | 4.9 | 101.2 | (32.6-236.2) |  | Female | 27 | 37.8 | 71.4 | (47.1-103.9) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 90 | 70.4 | 127.8 | (102.8-157.1) |  | Male | 553 | 508.4 | 108.8 | (99.9-118.2) |
| Female | 95 | 77.8 | 122.0 | (98.7-149.2) |  | Female | 606 | 541.0 | 112.0 | (103.3-121.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

116

# Goshen

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 2 | 1.3 | nc | (nc-nc) |  | Male | 0 | 0.9 | nc | (nc-nc) |
| Female | 1 | 0.4 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 1 | 0.8 | nc | (nc-nc) |
| Female | 5 | 5.8 | 86.8 | (28.0-202.5) |  | Female | 0 | 0.6 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 2 | 0.8 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 1 | 1.5 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 1.3 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 3 | 4.8 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 0.9 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 1 | 0.4 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 1 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 1 | 1.1 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 1 | 1.3 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 1 | 2.4 | nc | (nc-nc) |  | Male | 12 | 18.3 | 65.5 | (33.8-114.5) |
| Female | 0 | 2.3 | nc | (nc-nc) |  | Female | 10 | 18.2 | 54.8 | (26.2-100.8) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

117

# Gosnold

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 0 | 0.0 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  | Female | 0 | 0.0 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 0.0 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  | Female | 0 | 0.0 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 0 | 0.0 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 0.0 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.0 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 0 | 0.0 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 0 | 0.0 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.0 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 0 | 1.4 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 2.3 | nc | (nc-nc) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

118

# Grafton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 21 | 16.1 | 130.1 | (80.5-198.8) |  | Male | 11 | 11.2 | 98.4 | (49.1-176.1) |
| Female | 4 | 5.8 | nc | (nc-nc) |  | Female | 11 | 9.1 | 120.3 | (60.0-215.3) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 7 | 3.5 | 199.2 | (79.8-410.5) |  | Male | 2 | 3.5 | nc | (nc-nc) |
| Female | 5 | 3.0 | 168.4 | (54.3-392.9) |  | Female | 3 | 2.8 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 7 | 9.9 | 70.5 | (28.3-145.3) |
| Female | 74 | 74.4 | 99.5 | (78.1-124.9) |  | Female | 7 | 8.4 | 83.4 | (33.4-171.9) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 15 | 8.8 | 171.3 | (95.8-282.6) |
| Female | 3 | 2.7 | nc | (nc-nc) |  | Female | 5 | 3.8 | 130.9 | (42.2-305.5) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 7 | 18.4 | 38.0 | (15.2-78.3) |  |  |  |  |  |  |
| Female | 18 | 17.0 | 105.9 | (62.8-167.4) |  | Female | 2 | 6.2 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 4.3 | nc | (nc-nc) |  | Male | 3 | 6.3 | nc | (nc-nc) |
| Female | 1 | 1.2 | nc | (nc-nc) |  | Female | 2 | 5.9 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 1.4 | nc | (nc-nc) |  | Male | 63 | 51.9 | 121.4 | (93.3-155.4) |
| Female | 1 | 1.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 14 | 10.5 | 133.2 | (72.8-223.5) |  | Male | 1 | 4.0 | nc | (nc-nc) |
| Female | 5 | 5.7 | 87.3 | (28.1-203.7) |  | Female | 2 | 2.4 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 9 | 2.5 | 356.6 | (162.7-676.9) |  | Male | 1 | 3.0 | nc | (nc-nc) |
| Female | 2 | 0.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 9 | 7.0 | 127.7 | (58.3-242.4) |  | Male | 5 | 5.2 | 95.8 | (30.9-223.5) |
| Female | 12 | 4.9 | 243.7 | (125.8-425.7) |  | Female | 15 | 15.4 | 97.6 | (54.6-161.0) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 3 | 6.2 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 2.0 | nc | (nc-nc) |  | Female | 14 | 16.5 | 84.8 | (46.3-142.2) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 31 | 28.4 | 109.0 | (74.1-154.7) |  | Male | 226 | 220.0 | 102.7 | (89.7-117.0) |
| Female | 31 | 31.7 | 97.9 | (66.5-138.9) |  | Female | 237 | 238.5 | 99.4 | (87.1-112.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

119

# Granby

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 4 | 6.1 | nc | (nc-nc) |  | Male | 2 | 4.3 | nc | (nc-nc) |
| Female | 4 | 2.5 | nc | (nc-nc) |  | Female | 3 | 3.6 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 1.3 | nc | (nc-nc) |  | Male | 1 | 1.4 | nc | (nc-nc) |
| Female | 2 | 1.2 | nc | (nc-nc) |  | Female | 1 | 1.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 5 | 3.7 | 133.9 | (43.2-312.6) |
| Female | 23 | 29.0 | 79.3 | (50.2-118.9) |  | Female | 3 | 3.5 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 3 | 3.6 | nc | (nc-nc) |
| Female | 1 | 1.0 | nc | (nc-nc) |  | Female | 0 | 1.6 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 10 | 6.8 | 147.6 | (70.6-271.4) |  |  |  |  |  |  |
| Female | 8 | 7.2 | 110.7 | (47.7-218.2) |  | Female | 2 | 2.5 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 4 | 1.8 | nc | (nc-nc) |  | Male | 2 | 2.5 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 0 | 2.7 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.5 | nc | (nc-nc) |  | Male | 19 | 22.6 | 84.2 | (50.7-131.5) |
| Female | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 4 | 4.1 | nc | (nc-nc) |  | Male | 2 | 1.5 | nc | (nc-nc) |
| Female | 8 | 2.3 | 350.9 | (151.1-691.4) |  | Female | 0 | 1.0 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 1.1 | nc | (nc-nc) |  | Male | 2 | 0.8 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 4 | 2.6 | nc | (nc-nc) |  | Male | 1 | 1.9 | nc | (nc-nc) |
| Female | 1 | 2.1 | nc | (nc-nc) |  | Female | 1 | 5.6 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 2.7 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 2 | 0.8 | nc | (nc-nc) |  | Female | 6 | 6.7 | 89.2 | (32.6-194.2) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 14 | 11.5 | 121.9 | (66.6-204.5) |  | Male | 89 | 87.2 | 102.1 | (82.0-125.6) |
| Female | 12 | 12.8 | 93.6 | (48.3-163.6) |  | Female | 82 | 96.3 | 85.1 | (67.7-105.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

120

# Granville

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 4 | 2.3 | nc | (nc-nc) |  | Male | 1 | 1.4 | nc | (nc-nc) |
| Female | 1 | 0.6 | nc | (nc-nc) |  | Female | 2 | 0.9 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 1 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 1 | 0.3 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 4 | 1.3 | nc | (nc-nc) |
| Female | 7 | 7.4 | 94.4 | (37.8-194.5) |  | Female | 0 | 0.8 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 1.1 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 1 | 2.3 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 2 | 1.7 | nc | (nc-nc) |  | Female | 1 | 0.6 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 0 | 0.8 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.6 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 8 | 7.2 | 111.3 | (47.9-219.2) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 2 | 1.3 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 1 | 0.6 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 0.9 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 2 | 1.3 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 6 | 1.7 | 350.8 | (128.1-763.6) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 3 | 4.0 | nc | (nc-nc) |  | Male | 27 | 29.0 | 93.0 | (61.2-135.3) |
| Female | 4 | 3.1 | nc | (nc-nc) |  | Female | 28 | 23.3 | 120.0 | (79.7-173.4) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

121

# Great Barrington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 11 | 9.2 | 119.6 | (59.6-214.0) |  | Male | 9 | 5.7 | 159.1 | (72.6-301.9) |
| Female | 5 | 3.9 | 128.8 | (41.5-300.5) |  | Female | 3 | 4.6 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 1.6 | nc | (nc-nc) |  | Male | 4 | 1.8 | nc | (nc-nc) |
| Female | 5 | 1.5 | 333.0 | (107.3-777.0) |  | Female | 2 | 1.8 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.3 | nc | (nc-nc) |  | Male | 5 | 5.0 | 100.0 | (32.2-233.5) |
| Female | 45 | 37.7 | 119.5 | (87.2-159.9) |  | Female | 3 | 5.0 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 5 | 4.1 | 123.1 | (39.7-287.2) |
| Female | 2 | 1.1 | nc | (nc-nc) |  | Female | 2 | 2.2 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 7 | 9.1 | 76.6 | (30.7-157.7) |  |  |  |  |  |  |
| Female | 9 | 10.6 | 85.1 | (38.8-161.6) |  | Female | 3 | 3.3 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 2.3 | nc | (nc-nc) |  | Male | 3 | 3.3 | nc | (nc-nc) |
| Female | 0 | 0.8 | nc | (nc-nc) |  | Female | 4 | 4.1 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 27 | 26.6 | 101.4 | (66.8-147.5) |
| Female | 0 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 4 | 5.0 | nc | (nc-nc) |  | Male | 2 | 2.1 | nc | (nc-nc) |
| Female | 2 | 3.1 | nc | (nc-nc) |  | Female | 0 | 1.5 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 3 | 1.3 | nc | (nc-nc) |  | Male | 1 | 1.0 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 2 | 3.6 | nc | (nc-nc) |  | Male | 1 | 2.1 | nc | (nc-nc) |
| Female | 3 | 2.9 | nc | (nc-nc) |  | Female | 6 | 5.6 | 106.4 | (38.9-231.6) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 3.1 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 1.2 | nc | (nc-nc) |  | Female | 6 | 8.9 | 67.2 | (24.5-146.2) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 14 | 16.0 | 87.8 | (47.9-147.3) |  | Male | 115 | 112.8 | 102.0 | (84.2-122.4) |
| Female | 23 | 19.7 | 116.8 | (74.0-175.2) |  | Female | 134 | 131.7 | 101.7 | (85.2-120.5) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

122

# Greenfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 15 | 21.8 | 68.7 | (38.4-113.2) |  | Male | 10 | 13.7 | 72.8 | (34.8-133.8) |
| Female | 7 | 8.1 | 86.6 | (34.7-178.4) |  | Female | 7 | 10.6 | 66.1 | (26.5-136.1) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 6 | 4.0 | 151.4 | (55.3-329.5) |  | Male | 5 | 4.5 | 111.9 | (36.1-261.2) |
| Female | 5 | 3.4 | 146.6 | (47.3-342.2) |  | Female | 4 | 3.7 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  | Male | 6 | 12.2 | 49.2 | (18.0-107.0) |
| Female | 66 | 83.6 | 79.0 | (61.1-100.5) |  | Female | 7 | 10.8 | 64.7 | (25.9-133.2) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 13 | 10.2 | 127.8 | (68.0-218.6) |
| Female | 3 | 2.6 | nc | (nc-nc) |  | Female | 6 | 4.7 | 126.9 | (46.3-276.2) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 25 | 22.1 | 113.1 | (73.1-166.9) |  |  |  |  |  |  |
| Female | 27 | 22.9 | 118.1 | (77.8-171.8) |  | Female | 6 | 7.3 | 81.8 | (29.9-178.1) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 4 | 5.6 | nc | (nc-nc) |  | Male | 8 | 8.1 | 98.6 | (42.5-194.4) |
| Female | 3 | 1.6 | nc | (nc-nc) |  | Female | 9 | 8.5 | 105.3 | (48.0-199.9) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 5 | 1.5 | 343.2 | (110.6-801.0) |  | Male | 40 | 67.7 | 59.1 | (42.2-80.4) |
| Female | 2 | 1.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 9 | 12.3 | 73.0 | (33.3-138.5) |  | Male | 3 | 5.1 | nc | (nc-nc) |
| Female | 7 | 6.8 | 102.7 | (41.1-211.6) |  | Female | 2 | 3.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 3.3 | nc | (nc-nc) |  | Male | 2 | 2.6 | nc | (nc-nc) |
| Female | 1 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 7 | 8.6 | 81.3 | (32.6-167.6) |  | Male | 4 | 5.2 | nc | (nc-nc) |
| Female | 5 | 6.4 | 77.9 | (25.1-181.8) |  | Female | 3 | 14.6 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 6 | 7.8 | 76.9 | (28.1-167.4) |  |  |  |  |  |  |
| Female | 5 | 2.7 | 187.2 | (60.3-436.9) |  | Female | 23 | 19.3 | 119.2 | (75.5-178.8) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 34 | 38.5 | 88.4 | (61.2-123.5) |  | Male | 227 | 277.2 | 81.9 | (71.6-93.3) |
| Female | 49 | 40.9 | 119.9 | (88.7-158.5) |  | Female | 276 | 288.2 | 95.8 | (84.8-107.8) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

123

# Groton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 10 | 11.5 | 86.8 | (41.6-159.7) |  | Male | 5 | 7.8 | 64.0 | (20.6-149.4) |
| Female | 2 | 3.9 | nc | (nc-nc) |  | Female | 5 | 6.1 | 82.0 | (26.4-191.3) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 3 | 2.3 | nc | (nc-nc) |  | Male | 1 | 2.5 | nc | (nc-nc) |
| Female | 0 | 1.9 | nc | (nc-nc) |  | Female | 1 | 1.9 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.4 | nc | (nc-nc) |  | Male | 4 | 6.9 | nc | (nc-nc) |
| Female | 45 | 50.8 | 88.5 | (64.6-118.5) |  | Female | 7 | 5.7 | 122.7 | (49.2-252.8) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 5 | 6.3 | 79.4 | (25.6-185.2) |
| Female | 2 | 1.8 | nc | (nc-nc) |  | Female | 1 | 2.6 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 15 | 13.1 | 114.7 | (64.1-189.2) |  |  |  |  |  |  |
| Female | 12 | 11.8 | 101.8 | (52.5-177.9) |  | Female | 2 | 4.3 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 3.1 | nc | (nc-nc) |  | Male | 3 | 4.5 | nc | (nc-nc) |
| Female | 0 | 0.8 | nc | (nc-nc) |  | Female | 3 | 4.1 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  | Male | 29 | 38.4 | 75.5 | (50.6-108.4) |
| Female | 0 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 7 | 7.5 | 93.7 | (37.6-193.1) |  | Male | 2 | 2.8 | nc | (nc-nc) |
| Female | 3 | 3.9 | nc | (nc-nc) |  | Female | 2 | 1.6 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 1.8 | nc | (nc-nc) |  | Male | 5 | 1.5 | 326.7 | (105.3-762.3) |
| Female | 0 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 3 | 4.8 | nc | (nc-nc) |  | Male | 6 | 3.4 | 175.1 | (63.9-381.1) |
| Female | 0 | 3.3 | nc | (nc-nc) |  | Female | 9 | 9.8 | 91.5 | (41.8-173.7) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 4.5 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 1.4 | nc | (nc-nc) |  | Female | 10 | 11.4 | 87.5 | (41.9-160.9) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 9 | 20.4 | 44.1 | (20.1-83.8) |  | Male | 123 | 156.5 | 78.6 | (65.3-93.8) |
| Female | 13 | 21.1 | 61.7 | (32.8-105.5) |  | Female | 128 | 161.5 | 79.3 | (66.1-94.2) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

124

# Groveland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 6 | 9.3 | 64.7 | (23.6-140.8) |  | Male | 5 | 5.8 | 86.7 | (27.9-202.3) |
| Female | 3 | 2.9 | nc | (nc-nc) |  | Female | 12 | 3.9 | 304.8 | (157.3-532.5) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 1.6 | nc | (nc-nc) |  | Male | 0 | 1.9 | nc | (nc-nc) |
| Female | 0 | 1.3 | nc | (nc-nc) |  | Female | 1 | 1.4 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 9 | 5.1 | 176.0 | (80.3-334.2) |
| Female | 34 | 34.2 | 99.4 | (68.8-138.9) |  | Female | 4 | 3.9 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 2 | 4.1 | nc | (nc-nc) |
| Female | 2 | 1.0 | nc | (nc-nc) |  | Female | 2 | 1.8 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 3 | 9.4 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 5 | 8.0 | 62.6 | (20.2-146.2) |  | Female | 3 | 2.9 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 2.3 | nc | (nc-nc) |  | Male | 5 | 3.4 | 147.3 | (47.5-343.7) |
| Female | 1 | 0.6 | nc | (nc-nc) |  | Female | 3 | 3.0 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 30 | 27.1 | 110.6 | (74.6-157.9) |
| Female | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 2 | 5.1 | nc | (nc-nc) |  | Male | 3 | 2.1 | nc | (nc-nc) |
| Female | 3 | 2.7 | nc | (nc-nc) |  | Female | 4 | 1.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 1.4 | nc | (nc-nc) |  | Male | 1 | 1.0 | nc | (nc-nc) |
| Female | 1 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 3.6 | nc | (nc-nc) |  | Male | 6 | 2.1 | 285.9 | (104.4-622.2) |
| Female | 2 | 2.2 | nc | (nc-nc) |  | Female | 5 | 5.7 | 87.7 | (28.3-204.7) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 3.1 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 1.0 | nc | (nc-nc) |  | Female | 6 | 8.1 | 74.2 | (27.1-161.5) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 8 | 16.5 | 48.5 | (20.9-95.6) |  | Male | 94 | 114.8 | 81.9 | (66.2-100.2) |
| Female | 16 | 15.8 | 101.1 | (57.7-164.2) |  | Female | 113 | 110.6 | 102.2 | (84.2-122.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

125

# Hadley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 6 | 7.2 | 83.3 | (30.4-181.4) |  | Male | 2 | 4.2 | nc | (nc-nc) |
| Female | 1 | 3.4 | nc | (nc-nc) |  | Female | 1 | 4.1 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 1.1 | nc | (nc-nc) |  | Male | 1 | 1.4 | nc | (nc-nc) |
| Female | 0 | 1.3 | nc | (nc-nc) |  | Female | 0 | 1.5 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 2 | 3.7 | nc | (nc-nc) |
| Female | 28 | 32.4 | 86.4 | (57.4-124.9) |  | Female | 4 | 4.4 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 8 | 2.9 | 273.6 | (117.8-539.2) |
| Female | 1 | 1.0 | nc | (nc-nc) |  | Female | 0 | 1.9 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 6 | 7.0 | 85.7 | (31.3-186.6) |  |  |  |  |  |  |
| Female | 8 | 9.4 | 85.4 | (36.8-168.2) |  | Female | 3 | 2.9 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 1.7 | nc | (nc-nc) |  | Male | 2 | 2.5 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 1 | 3.6 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 19 | 19.5 | 97.5 | (58.7-152.3) |
| Female | 0 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 3 | 3.6 | nc | (nc-nc) |  | Male | 1 | 1.6 | nc | (nc-nc) |
| Female | 3 | 2.7 | nc | (nc-nc) |  | Female | 0 | 1.3 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.9 | nc | (nc-nc) |  | Male | 0 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 2 | 2.6 | nc | (nc-nc) |  | Male | 1 | 1.4 | nc | (nc-nc) |
| Female | 3 | 2.6 | nc | (nc-nc) |  | Female | 3 | 5.1 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 2.2 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 1.1 | nc | (nc-nc) |  | Female | 12 | 7.5 | 159.3 | (82.2-278.2) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 7 | 12.2 | 57.5 | (23.0-118.5) |  | Male | 69 | 84.1 | 82.1 | (63.8-103.8) |
| Female | 7 | 17.0 | 41.1 | (16.5-84.7) |  | Female | 81 | 114.8 | 70.6 | (56.0-87.7) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

126

# Halifax

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 6 | 8.2 | 72.8 | (26.6-158.4) |  | Male | 4 | 5.4 | nc | (nc-nc) |
| Female | 1 | 3.1 | nc | (nc-nc) |  | Female | 5 | 4.3 | 115.4 | (37.2-269.3) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 1.6 | nc | (nc-nc) |  | Male | 2 | 1.7 | nc | (nc-nc) |
| Female | 2 | 1.4 | nc | (nc-nc) |  | Female | 1 | 1.4 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 5 | 4.8 | 104.0 | (33.5-242.8) |
| Female | 40 | 35.4 | 112.8 | (80.6-153.7) |  | Female | 6 | 4.3 | 138.5 | (50.6-301.5) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 5 | 3.9 | 127.2 | (41.0-296.9) |
| Female | 1 | 1.2 | nc | (nc-nc) |  | Female | 2 | 1.8 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 15 | 8.8 | 170.3 | (95.3-281.0) |  |  |  |  |  |  |
| Female | 11 | 8.9 | 124.0 | (61.8-221.9) |  | Female | 2 | 3.0 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 2.1 | nc | (nc-nc) |  | Male | 7 | 3.1 | 229.2 | (91.8-472.3) |
| Female | 1 | 0.6 | nc | (nc-nc) |  | Female | 3 | 3.1 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 28 | 23.6 | 118.5 | (78.7-171.3) |
| Female | 0 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 9 | 4.9 | 185.3 | (84.5-351.8) |  | Male | 1 | 2.0 | nc | (nc-nc) |
| Female | 5 | 2.8 | 177.9 | (57.3-415.1) |  | Female | 2 | 1.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 1.2 | nc | (nc-nc) |  | Male | 3 | 1.2 | nc | (nc-nc) |
| Female | 1 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 4 | 3.3 | nc | (nc-nc) |  | Male | 3 | 2.2 | nc | (nc-nc) |
| Female | 2 | 2.5 | nc | (nc-nc) |  | Female | 12 | 6.5 | 183.4 | (94.7-320.4) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 5 | 2.9 | 173.8 | (56.0-405.6) |  |  |  |  |  |  |
| Female | 3 | 1.0 | nc | (nc-nc) |  | Female | 17 | 7.7 | 220.8 | (128.6-353.6) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 19 | 14.6 | 129.8 | (78.1-202.7) |  | Male | 130 | 104.9 | 123.9 | (103.6-147.2) |
| Female | 17 | 16.4 | 103.4 | (60.2-165.5) |  | Female | 144 | 116.9 | 123.1 | (103.9-145.0) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

127

# Hamilton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 4 | 8.8 | nc | (nc-nc) |  | Male | 5 | 5.8 | 86.6 | (27.9-202.0) |
| Female | 5 | 3.0 | 167.2 | (53.9-390.3) |  | Female | 9 | 4.3 | 210.9 | (96.3-400.4) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 1.8 | nc | (nc-nc) |  | Male | 2 | 1.9 | nc | (nc-nc) |
| Female | 1 | 1.4 | nc | (nc-nc) |  | Female | 0 | 1.4 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 2 | 5.1 | nc | (nc-nc) |
| Female | 41 | 35.2 | 116.4 | (83.5-158.0) |  | Female | 10 | 4.1 | 241.7 | (115.7-444.5) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 3 | 4.3 | nc | (nc-nc) |
| Female | 0 | 1.1 | nc | (nc-nc) |  | Female | 0 | 1.9 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 2 | 9.5 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 11 | 8.7 | 126.5 | (63.1-226.4) |  | Female | 1 | 3.0 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 2.3 | nc | (nc-nc) |  | Male | 1 | 3.3 | nc | (nc-nc) |
| Female | 1 | 0.6 | nc | (nc-nc) |  | Female | 1 | 3.1 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.7 | nc | (nc-nc) |  | Male | 24 | 26.7 | 90.0 | (57.7-134.0) |
| Female | 0 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 6 | 5.3 | 113.3 | (41.4-246.7) |  | Male | 1 | 2.1 | nc | (nc-nc) |
| Female | 3 | 2.8 | nc | (nc-nc) |  | Female | 0 | 1.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 1.3 | nc | (nc-nc) |  | Male | 1 | 1.2 | nc | (nc-nc) |
| Female | 1 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 4 | 3.6 | nc | (nc-nc) |  | Male | 5 | 2.4 | 208.6 | (67.2-486.9) |
| Female | 3 | 2.4 | nc | (nc-nc) |  | Female | 7 | 6.4 | 109.8 | (44.0-226.3) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 3.1 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 1.0 | nc | (nc-nc) |  | Female | 6 | 8.0 | 75.1 | (27.4-163.5) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 8 | 15.6 | 51.2 | (22.0-100.8) |  | Male | 79 | 114.2 | 69.2 | (54.8-86.2) |
| Female | 13 | 16.0 | 81.3 | (43.2-139.0) |  | Female | 125 | 115.3 | 108.4 | (90.2-129.1) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

128

# Hampden

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 6 | 8.8 | 68.5 | (25.0-149.1) |  | Male | 1 | 5.3 | nc | (nc-nc) |
| Female | 0 | 2.6 | nc | (nc-nc) |  | Female | 1 | 3.4 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 1.4 | nc | (nc-nc) |  | Male | 1 | 1.8 | nc | (nc-nc) |
| Female | 1 | 1.1 | nc | (nc-nc) |  | Female | 2 | 1.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 7 | 4.7 | 149.5 | (59.9-308.1) |
| Female | 26 | 27.9 | 93.2 | (60.9-136.6) |  | Female | 2 | 3.4 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 3.7 | nc | (nc-nc) |
| Female | 1 | 0.9 | nc | (nc-nc) |  | Female | 2 | 1.5 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 2 | 8.5 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 5 | 7.3 | 68.1 | (21.9-158.9) |  | Female | 2 | 2.4 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 2.1 | nc | (nc-nc) |  | Male | 2 | 3.2 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 3 | 2.7 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 22 | 25.0 | 87.9 | (55.1-133.1) |
| Female | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 5 | 4.6 | 108.7 | (35.0-253.6) |  | Male | 0 | 2.0 | nc | (nc-nc) |
| Female | 0 | 2.2 | nc | (nc-nc) |  | Female | 0 | 1.0 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 1.3 | nc | (nc-nc) |  | Male | 6 | 0.6 | 1007.6 | (367.9-2193.2) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 2 | 3.2 | nc | (nc-nc) |  | Male | 1 | 1.7 | nc | (nc-nc) |
| Female | 1 | 2.0 | nc | (nc-nc) |  | Female | 5 | 4.7 | 106.3 | (34.3-248.2) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 3 | 2.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.8 | nc | (nc-nc) |  | Female | 5 | 6.3 | 79.2 | (25.5-184.9) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 6 | 15.6 | 38.5 | (14.0-83.7) |  | Male | 70 | 105.6 | 66.3 | (51.7-83.8) |
| Female | 9 | 13.3 | 67.6 | (30.8-128.3) |  | Female | 69 | 93.4 | 73.8 | (57.5-93.5) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

129

# Hancock

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 1 | 1.0 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 1 | 0.3 | nc | (nc-nc) |  | Female | 1 | 0.4 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 1 | 0.6 | nc | (nc-nc) |
| Female | 2 | 3.5 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 0 | 1.0 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.8 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 3 | 3.1 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 1 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.6 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 2 | 0.8 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 0 | 1.8 | nc | (nc-nc) |  | Male | 9 | 12.7 | 71.1 | (32.5-135.1) |
| Female | 3 | 1.6 | nc | (nc-nc) |  | Female | 11 | 11.4 | 96.5 | (48.1-172.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

130

# Hanover

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 17 | 13.1 | 129.4 | (75.4-207.2) |  | Male | 23 | 8.9 | 259.5 | (164.5-389.5) |
| Female | 6 | 5.4 | 111.9 | (40.8-243.5) |  | Female | 6 | 7.8 | 77.0 | (28.1-167.7) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 4 | 2.8 | nc | (nc-nc) |  | Male | 2 | 2.8 | nc | (nc-nc) |
| Female | 2 | 2.6 | nc | (nc-nc) |  | Female | 4 | 2.5 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 4 | 7.9 | nc | (nc-nc) |
| Female | 82 | 64.1 | 128.0 | (101.8-158.9) |  | Female | 8 | 7.5 | 106.2 | (45.7-209.2) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 6 | 6.8 | 87.6 | (32.0-190.7) |
| Female | 0 | 2.2 | nc | (nc-nc) |  | Female | 2 | 3.4 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 18 | 14.2 | 126.4 | (74.9-199.8) |  |  |  |  |  |  |
| Female | 16 | 15.4 | 104.2 | (59.5-169.2) |  | Female | 6 | 5.4 | 111.9 | (40.9-243.5) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 5 | 3.5 | 141.4 | (45.6-330.1) |  | Male | 1 | 5.0 | nc | (nc-nc) |
| Female | 1 | 1.1 | nc | (nc-nc) |  | Female | 2 | 5.6 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 1.0 | nc | (nc-nc) |  | Male | 53 | 42.9 | 123.5 | (92.5-161.6) |
| Female | 0 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 4 | 8.4 | nc | (nc-nc) |  | Male | 1 | 3.2 | nc | (nc-nc) |
| Female | 5 | 5.0 | 99.9 | (32.2-233.0) |  | Female | 0 | 2.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 2.0 | nc | (nc-nc) |  | Male | 2 | 2.1 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 10 | 5.7 | 176.6 | (84.6-324.8) |  | Male | 6 | 4.0 | 151.0 | (55.1-328.6) |
| Female | 2 | 4.4 | nc | (nc-nc) |  | Female | 13 | 12.1 | 107.1 | (57.0-183.2) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 5.0 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 1.8 | nc | (nc-nc) |  | Female | 18 | 14.5 | 123.9 | (73.4-195.7) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 17 | 23.6 | 72.1 | (42.0-115.5) |  | Male | 184 | 177.1 | 103.9 | (89.4-120.1) |
| Female | 31 | 28.7 | 108.1 | (73.4-153.4) |  | Female | 214 | 209.5 | 102.1 | (88.9-116.8) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

131

# Hanson

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 10 | 10.7 | 93.2 | (44.6-171.5) |  | Male | 6 | 7.3 | 82.6 | (30.2-179.7) |
| Female | 4 | 3.3 | nc | (nc-nc) |  | Female | 4 | 5.2 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 3 | 2.2 | nc | (nc-nc) |  | Male | 1 | 2.4 | nc | (nc-nc) |
| Female | 0 | 1.7 | nc | (nc-nc) |  | Female | 2 | 1.6 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 2 | 6.4 | nc | (nc-nc) |
| Female | 37 | 44.6 | 83.0 | (58.4-114.4) |  | Female | 3 | 4.9 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 11 | 5.8 | 189.3 | (94.3-338.7) |
| Female | 0 | 1.5 | nc | (nc-nc) |  | Female | 4 | 2.3 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 13 | 11.7 | 111.5 | (59.3-190.7) |  |  |  |  |  |  |
| Female | 9 | 9.5 | 95.0 | (43.3-180.3) |  | Female | 4 | 3.6 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 3.0 | nc | (nc-nc) |  | Male | 4 | 4.2 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 1 | 3.4 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  | Male | 31 | 37.4 | 83.0 | (56.4-117.8) |
| Female | 0 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 3 | 7.0 | nc | (nc-nc) |  | Male | 1 | 2.6 | nc | (nc-nc) |
| Female | 8 | 3.4 | 236.2 | (101.7-465.4) |  | Female | 0 | 1.4 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 1.8 | nc | (nc-nc) |  | Male | 3 | 1.5 | nc | (nc-nc) |
| Female | 1 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 4.5 | nc | (nc-nc) |  | Male | 2 | 3.1 | nc | (nc-nc) |
| Female | 4 | 2.8 | nc | (nc-nc) |  | Female | 6 | 8.7 | 69.3 | (25.3-150.8) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 4 | 4.3 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 2 | 1.2 | nc | (nc-nc) |  | Female | 9 | 10.2 | 87.8 | (40.1-166.7) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 25 | 19.9 | 125.7 | (81.3-185.6) |  | Male | 137 | 147.7 | 92.7 | (77.9-109.6) |
| Female | 26 | 18.9 | 137.7 | (89.9-201.8) |  | Female | 137 | 140.0 | 97.9 | (82.2-115.7) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

132

# Hardwick

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 0 | 4.9 | nc | (nc-nc) |  | Male | 4 | 3.1 | nc | (nc-nc) |
| Female | 1 | 1.0 | nc | (nc-nc) |  | Female | 1 | 1.6 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 0.9 | nc | (nc-nc) |  | Male | 0 | 1.0 | nc | (nc-nc) |
| Female | 2 | 0.5 | nc | (nc-nc) |  | Female | 1 | 0.5 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 2 | 2.7 | nc | (nc-nc) |
| Female | 13 | 13.3 | 97.8 | (52.0-167.3) |  | Female | 1 | 1.5 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 2.3 | nc | (nc-nc) |
| Female | 1 | 0.4 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 5 | 4.9 | 101.8 | (32.8-237.5) |  |  |  |  |  |  |
| Female | 3 | 2.9 | nc | (nc-nc) |  | Female | 0 | 1.1 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 1.3 | nc | (nc-nc) |  | Male | 3 | 1.8 | nc | (nc-nc) |
| Female | 1 | 0.2 | nc | (nc-nc) |  | Female | 0 | 1.1 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 6 | 16.3 | 36.8 | (13.4-80.2) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 2 | 2.9 | nc | (nc-nc) |  | Male | 0 | 1.1 | nc | (nc-nc) |
| Female | 0 | 1.0 | nc | (nc-nc) |  | Female | 1 | 0.4 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  | Male | 1 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 1.9 | nc | (nc-nc) |  | Male | 0 | 1.1 | nc | (nc-nc) |
| Female | 2 | 0.8 | nc | (nc-nc) |  | Female | 1 | 2.4 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 1.8 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 4 | 3.2 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 10 | 9.0 | 110.6 | (53.0-203.5) |  | Male | 44 | 63.3 | 69.5 | (50.5-93.3) |
| Female | 9 | 5.8 | 156.2 | (71.3-296.6) |  | Female | 43 | 42.2 | 101.8 | (73.7-137.2) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

133

# Harvard

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 5 | 9.1 | 54.9 | (17.7-128.1) |  | Male | 3 | 6.1 | nc | (nc-nc) |
| Female | 0 | 1.8 | nc | (nc-nc) |  | Female | 3 | 2.9 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 1.8 | nc | (nc-nc) |  | Male | 4 | 2.0 | nc | (nc-nc) |
| Female | 3 | 0.9 | nc | (nc-nc) |  | Female | 1 | 0.9 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.3 | nc | (nc-nc) |  | Male | 7 | 5.3 | 130.9 | (52.4-269.8) |
| Female | 28 | 24.7 | 113.5 | (75.4-164.1) |  | Female | 3 | 2.7 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 5 | 4.8 | 104.0 | (33.5-242.6) |
| Female | 0 | 0.8 | nc | (nc-nc) |  | Female | 0 | 1.2 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 3 | 9.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 10 | 5.4 | 184.9 | (88.5-340.1) |  | Female | 2 | 2.0 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 2.5 | nc | (nc-nc) |  | Male | 3 | 3.5 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 1 | 1.9 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 22 | 31.0 | 70.9 | (44.4-107.4) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 2 | 5.8 | nc | (nc-nc) |  | Male | 2 | 2.2 | nc | (nc-nc) |
| Female | 1 | 1.9 | nc | (nc-nc) |  | Female | 1 | 0.7 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 1.5 | nc | (nc-nc) |  | Male | 0 | 1.2 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 4 | 3.6 | nc | (nc-nc) |  | Male | 2 | 2.6 | nc | (nc-nc) |
| Female | 1 | 1.5 | nc | (nc-nc) |  | Female | 4 | 4.7 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 3.5 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 4 | 5.6 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 5 | 16.5 | 30.3 | (9.8-70.8) |  | Male | 87 | 123.0 | 70.7 | (56.7-87.3) |
| Female | 8 | 10.0 | 80.1 | (34.5-157.8) |  | Female | 76 | 76.8 | 99.0 | (78.0-123.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

134

# Harwich

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 29 | 23.3 | 124.5 | (83.4-178.9) |  | Male | 26 | 13.3 | 194.8 | (127.2-285.4) |
| Female | 7 | 8.5 | 82.4 | (33.0-169.8) |  | Female | 17 | 9.8 | 173.8 | (101.2-278.3) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 4 | 3.4 | nc | (nc-nc) |  | Male | 8 | 4.4 | 180.8 | (77.9-356.3) |
| Female | 5 | 3.1 | 158.9 | (51.2-370.9) |  | Female | 7 | 3.8 | 184.0 | (73.7-379.2) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.8 | nc | (nc-nc) |  | Male | 18 | 11.7 | 153.3 | (90.8-242.3) |
| Female | 109 | 81.7 | 133.4 | (109.5-160.9) |  | Female | 7 | 10.8 | 64.6 | (25.9-133.2) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 8 | 8.8 | 90.4 | (38.9-178.2) |
| Female | 0 | 2.2 | nc | (nc-nc) |  | Female | 5 | 4.6 | 107.7 | (34.7-251.3) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 25 | 21.5 | 116.0 | (75.1-171.3) |  |  |  |  |  |  |
| Female | 37 | 22.3 | 165.8 | (116.7-228.6) |  | Female | 4 | 7.1 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 6 | 5.4 | 111.4 | (40.7-242.5) |  | Male | 6 | 8.1 | 74.2 | (27.1-161.5) |
| Female | 0 | 1.6 | nc | (nc-nc) |  | Female | 8 | 8.8 | 91.2 | (39.3-179.7) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 3 | 1.0 | nc | (nc-nc) |  | Male | 90 | 62.1 | 144.8 | (116.5-178.0) |
| Female | 0 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 12 | 11.2 | 107.2 | (55.3-187.3) |  | Male | 7 | 5.1 | 137.3 | (55.0-282.9) |
| Female | 5 | 6.9 | 72.7 | (23.4-169.7) |  | Female | 1 | 3.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 3 | 3.1 | nc | (nc-nc) |  | Male | 0 | 1.5 | nc | (nc-nc) |
| Female | 1 | 1.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 10 | 8.3 | 120.9 | (57.9-222.3) |  | Male | 7 | 4.0 | 174.1 | (69.8-358.8) |
| Female | 7 | 6.1 | 113.9 | (45.6-234.8) |  | Female | 5 | 11.5 | 43.3 | (14.0-101.1) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 6 | 6.9 | 86.4 | (31.5-188.0) |  |  |  |  |  |  |
| Female | 3 | 2.7 | nc | (nc-nc) |  | Female | 20 | 19.2 | 104.0 | (63.5-160.6) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 44 | 40.1 | 109.6 | (79.6-147.2) |  | Male | 336 | 266.0 | 126.3 | (113.2-140.6) |
| Female | 46 | 44.8 | 102.7 | (75.1-136.9) |  | Female | 327 | 284.5 | 114.9 | (102.8-128.1) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

135

# Hatfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 5 | 5.3 | 94.2 | (30.4-219.9) |  | Male | 4 | 3.3 | nc | (nc-nc) |
| Female | 3 | 1.6 | nc | (nc-nc) |  | Female | 1 | 2.2 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 0.9 | nc | (nc-nc) |  | Male | 1 | 1.1 | nc | (nc-nc) |
| Female | 1 | 0.7 | nc | (nc-nc) |  | Female | 2 | 0.7 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 1 | 2.9 | nc | (nc-nc) |
| Female | 21 | 18.9 | 111.3 | (68.9-170.1) |  | Female | 3 | 2.2 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 2.4 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 1 | 1.0 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 5 | 5.3 | 94.9 | (30.6-221.5) |  |  |  |  |  |  |
| Female | 9 | 4.5 | 200.5 | (91.5-380.6) |  | Female | 3 | 1.6 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 1.3 | nc | (nc-nc) |  | Male | 4 | 1.9 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 1 | 1.6 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.3 | nc | (nc-nc) |  | Male | 16 | 16.3 | 98.1 | (56.0-159.3) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 6 | 3.0 | 201.9 | (73.7-439.5) |  | Male | 3 | 1.2 | nc | (nc-nc) |
| Female | 6 | 1.5 | 400.0 | (146.1-870.7) |  | Female | 0 | 0.6 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 2 | 2.0 | nc | (nc-nc) |  | Male | 1 | 1.1 | nc | (nc-nc) |
| Female | 0 | 1.2 | nc | (nc-nc) |  | Female | 2 | 3.2 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 1.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 0.5 | nc | (nc-nc) |  | Female | 5 | 4.3 | 115.4 | (37.2-269.3) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 9 | 9.8 | 92.2 | (42.1-175.0) |  | Male | 63 | 66.5 | 94.8 | (72.8-121.2) |
| Female | 8 | 9.0 | 88.8 | (38.2-174.9) |  | Female | 72 | 61.4 | 117.4 | (91.8-147.8) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

136

# Haverhill

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 54 | 61.0 | 88.5 | (66.5-115.5) |  | Male | 29 | 39.9 | 72.7 | (48.7-104.5) |
| Female | 33 | 21.5 | 153.6 | (105.7-215.7) |  | Female | 17 | 32.2 | 52.8 | (30.7-84.5) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 14 | 12.1 | 115.4 | (63.0-193.6) |  | Male | 8 | 12.6 | 63.5 | (27.3-125.0) |
| Female | 16 | 10.5 | 152.1 | (86.9-247.0) |  | Female | 10 | 10.2 | 98.2 | (47.0-180.7) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 3 | 2.1 | nc | (nc-nc) |  | Male | 36 | 35.6 | 101.2 | (70.9-140.2) |
| Female | 242 | 255.2 | 94.8 | (83.3-107.6) |  | Female | 39 | 30.4 | 128.5 | (91.4-175.7) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 27 | 30.0 | 90.0 | (59.3-131.0) |
| Female | 9 | 8.8 | 102.1 | (46.6-193.8) |  | Female | 12 | 13.7 | 87.7 | (45.3-153.3) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 64 | 65.9 | 97.2 | (74.8-124.1) |  |  |  |  |  |  |
| Female | 71 | 63.5 | 111.8 | (87.3-141.0) |  | Female | 18 | 22.0 | 81.9 | (48.5-129.4) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 13 | 15.5 | 84.1 | (44.7-143.8) |  | Male | 23 | 22.8 | 101.1 | (64.1-151.7) |
| Female | 8 | 4.2 | 188.9 | (81.3-372.3) |  | Female | 28 | 22.5 | 124.2 | (82.5-179.6) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 6 | 5.0 | 120.5 | (44.0-262.3) |  | Male | 156 | 183.1 | 85.2 | (72.4-99.7) |
| Female | 4 | 4.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 36 | 35.9 | 100.2 | (70.1-138.7) |  | Male | 18 | 14.5 | 124.5 | (73.7-196.8) |
| Female | 23 | 20.1 | 114.4 | (72.5-171.7) |  | Female | 7 | 8.9 | 79.0 | (31.7-162.8) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 12 | 8.9 | 134.4 | (69.4-234.7) |  | Male | 7 | 9.8 | 71.3 | (28.6-146.9) |
| Female | 5 | 2.8 | 179.0 | (57.7-417.8) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 22 | 25.4 | 86.8 | (54.4-131.4) |  | Male | 16 | 17.0 | 94.3 | (53.9-153.2) |
| Female | 22 | 18.4 | 119.6 | (74.9-181.1) |  | Female | 61 | 50.6 | 120.5 | (92.1-154.8) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 16 | 22.2 | 72.2 | (41.3-117.3) |  |  |  |  |  |  |
| Female | 6 | 7.4 | 81.6 | (29.8-177.6) |  | Female | 69 | 57.6 | 119.8 | (93.2-151.6) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 116 | 104.3 | 111.2 | (91.9-133.4) |  | Male | 723 | 787.2 | 91.8 | (85.3-98.8) |
| Female | 134 | 112.5 | 119.1 | (99.8-141.1) |  | Female | 895 | 843.6 | 106.1 | (99.2-113.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

137

# Hawley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 2 | 0.7 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 3 | 2.0 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 2 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 1 | 2.3 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 1 | 1.4 | nc | (nc-nc) |  | Male | 6 | 9.2 | 65.5 | (23.9-142.6) |
| Female | 0 | 0.9 | nc | (nc-nc) |  | Female | 3 | 6.3 | nc | (nc-nc) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

138

# Heath

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 3 | 1.1 | nc | (nc-nc) |  | Male | 0 | 0.7 | nc | (nc-nc) |
| Female | 1 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 1 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 1 | 0.6 | nc | (nc-nc) |
| Female | 2 | 3.6 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 0 | 1.1 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.8 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 2 | 3.6 | nc | (nc-nc) |
| Female | 1 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 1 | 0.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 0.4 | nc | (nc-nc) |  | Male | 1 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 1 | 0.6 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 3 | 0.9 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 3 | 1.9 | nc | (nc-nc) |  | Male | 12 | 14.0 | 85.9 | (44.4-150.1) |
| Female | 1 | 1.7 | nc | (nc-nc) |  | Female | 11 | 11.5 | 95.4 | (47.5-170.7) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

139

# Hingham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 32 | 31.5 | 101.6 | (69.5-143.4) |  | Male | 34 | 19.1 | 178.4 | (123.5-249.3) |
| Female | 12 | 11.8 | 101.6 | (52.4-177.5) |  | Female | 31 | 14.8 | 208.9 | (141.9-296.5) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 8 | 5.2 | 154.0 | (66.3-303.6) |  | Male | 7 | 6.1 | 115.5 | (46.3-238.0) |
| Female | 5 | 4.7 | 105.7 | (34.1-246.7) |  | Female | 5 | 5.4 | 92.4 | (29.8-215.6) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 1.0 | nc | (nc-nc) |  | Male | 14 | 16.7 | 83.6 | (45.7-140.3) |
| Female | 108 | 119.5 | 90.4 | (74.1-109.1) |  | Female | 21 | 15.5 | 135.5 | (83.8-207.1) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 14 | 13.3 | 105.4 | (57.6-176.9) |
| Female | 3 | 3.6 | nc | (nc-nc) |  | Female | 6 | 6.8 | 88.8 | (32.4-193.3) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 35 | 31.8 | 110.2 | (76.7-153.2) |  |  |  |  |  |  |
| Female | 36 | 33.8 | 106.6 | (74.6-147.5) |  | Female | 9 | 10.5 | 85.8 | (39.2-163.0) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 7.3 | nc | (nc-nc) |  | Male | 9 | 11.2 | 80.4 | (36.7-152.7) |
| Female | 7 | 2.3 | 311.1 | (124.6-640.9) |  | Female | 14 | 12.6 | 111.4 | (60.8-186.8) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 1.7 | nc | (nc-nc) |  | Male | 93 | 83.8 | 110.9 | (89.5-135.9) |
| Female | 1 | 1.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 16 | 16.3 | 97.9 | (55.9-159.0) |  | Male | 12 | 7.1 | 168.6 | (87.0-294.5) |
| Female | 7 | 9.8 | 71.5 | (28.6-147.3) |  | Female | 1 | 4.7 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 4.2 | nc | (nc-nc) |  | Male | 6 | 3.1 | 193.1 | (70.5-420.2) |
| Female | 0 | 1.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 14 | 12.0 | 116.6 | (63.7-195.6) |  | Male | 4 | 6.8 | nc | (nc-nc) |
| Female | 14 | 9.3 | 151.3 | (82.6-253.9) |  | Female | 22 | 19.4 | 113.3 | (71.0-171.6) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 9.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 3.8 | nc | (nc-nc) |  | Female | 19 | 26.9 | 70.6 | (42.5-110.2) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 28 | 52.9 | 52.9 | (35.2-76.5) |  | Male | 368 | 372.3 | 98.8 | (89.0-109.5) |
| Female | 46 | 59.6 | 77.2 | (56.5-103.0) |  | Female | 395 | 412.8 | 95.7 | (86.5-105.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

140

# Hinsdale

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 4 | 2.7 | nc | (nc-nc) |  | Male | 0 | 1.8 | nc | (nc-nc) |
| Female | 1 | 0.8 | nc | (nc-nc) |  | Female | 1 | 1.2 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 1 | 0.6 | nc | (nc-nc) |
| Female | 1 | 0.4 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 3 | 1.6 | nc | (nc-nc) |
| Female | 15 | 9.9 | 152.0 | (85.0-250.8) |  | Female | 2 | 1.1 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 1.4 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 1 | 0.5 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 3 | 3.0 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 4 | 2.4 | nc | (nc-nc) |  | Female | 1 | 0.8 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 0.7 | nc | (nc-nc) |  | Male | 1 | 1.1 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.9 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 10 | 8.8 | 113.0 | (54.1-207.8) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 3 | 1.7 | nc | (nc-nc) |  | Male | 1 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.8 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 1.1 | nc | (nc-nc) |  | Male | 0 | 0.7 | nc | (nc-nc) |
| Female | 1 | 0.6 | nc | (nc-nc) |  | Female | 4 | 1.8 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 1.1 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 2 | 2.3 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 5 | 4.8 | 103.6 | (33.4-241.9) |  | Male | 34 | 36.2 | 93.9 | (65.0-131.3) |
| Female | 6 | 4.4 | 136.5 | (49.8-297.1) |  | Female | 41 | 31.9 | 128.6 | (92.3-174.4) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

141

# Holbrook

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 17 | 13.6 | 125.2 | (72.9-200.5) |  | Male | 5 | 8.6 | 57.9 | (18.7-135.1) |
| Female | 7 | 4.7 | 148.2 | (59.4-305.4) |  | Female | 1 | 6.6 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 4 | 2.5 | nc | (nc-nc) |  | Male | 4 | 2.8 | nc | (nc-nc) |
| Female | 4 | 2.1 | nc | (nc-nc) |  | Female | 6 | 2.2 | 275.6 | (100.6-599.9) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 10 | 7.6 | 131.8 | (63.1-242.3) |
| Female | 55 | 54.3 | 101.3 | (76.3-131.9) |  | Female | 10 | 6.4 | 155.1 | (74.2-285.2) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 6 | 6.2 | 96.8 | (35.3-210.7) |
| Female | 4 | 1.7 | nc | (nc-nc) |  | Female | 2 | 2.9 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 18 | 14.1 | 127.5 | (75.5-201.5) |  |  |  |  |  |  |
| Female | 19 | 13.3 | 143.3 | (86.2-223.7) |  | Female | 10 | 4.6 | 216.4 | (103.6-397.9) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 7 | 3.3 | 210.4 | (84.3-433.4) |  | Male | 3 | 4.9 | nc | (nc-nc) |
| Female | 0 | 0.9 | nc | (nc-nc) |  | Female | 5 | 4.8 | 103.8 | (33.4-242.2) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 1.0 | nc | (nc-nc) |  | Male | 41 | 37.8 | 108.4 | (77.8-147.1) |
| Female | 1 | 0.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 12 | 7.5 | 159.5 | (82.3-278.6) |  | Male | 3 | 3.2 | nc | (nc-nc) |
| Female | 4 | 4.3 | nc | (nc-nc) |  | Female | 1 | 1.9 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 1.9 | nc | (nc-nc) |  | Male | 1 | 1.8 | nc | (nc-nc) |
| Female | 2 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 5 | 5.3 | 93.5 | (30.1-218.1) |  | Male | 1 | 3.3 | nc | (nc-nc) |
| Female | 6 | 3.6 | 165.1 | (60.3-359.5) |  | Female | 6 | 9.9 | 60.7 | (22.2-132.2) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 6 | 4.6 | 129.0 | (47.1-280.9) |  |  |  |  |  |  |
| Female | 1 | 1.6 | nc | (nc-nc) |  | Female | 10 | 12.3 | 81.4 | (39.0-149.7) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 20 | 23.5 | 85.0 | (51.9-131.2) |  | Male | 177 | 167.9 | 105.5 | (90.5-122.2) |
| Female | 32 | 25.7 | 124.4 | (85.1-175.7) |  | Female | 195 | 178.8 | 109.0 | (94.3-125.5) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

142

# Holden

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 14 | 19.8 | 70.7 | (38.6-118.7) |  | Male | 19 | 12.9 | 147.2 | (88.6-229.9) |
| Female | 14 | 6.8 | 206.3 | (112.7-346.1) |  | Female | 13 | 9.9 | 130.8 | (69.6-223.7) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 4 | 3.9 | nc | (nc-nc) |  | Male | 7 | 4.2 | 168.3 | (67.4-346.9) |
| Female | 4 | 3.2 | nc | (nc-nc) |  | Female | 3 | 3.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.7 | nc | (nc-nc) |  | Male | 11 | 11.4 | 96.2 | (47.9-172.1) |
| Female | 93 | 80.4 | 115.7 | (93.4-141.8) |  | Female | 8 | 9.6 | 83.6 | (36.0-164.8) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 14 | 9.9 | 141.6 | (77.3-237.6) |
| Female | 1 | 2.7 | nc | (nc-nc) |  | Female | 6 | 4.3 | 140.0 | (51.1-304.7) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 18 | 21.2 | 84.8 | (50.2-134.0) |  |  |  |  |  |  |
| Female | 14 | 19.8 | 70.7 | (38.6-118.6) |  | Female | 7 | 6.9 | 101.9 | (40.8-210.0) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 7 | 5.1 | 136.6 | (54.7-281.4) |  | Male | 12 | 7.5 | 161.0 | (83.1-281.2) |
| Female | 2 | 1.3 | nc | (nc-nc) |  | Female | 8 | 7.1 | 113.0 | (48.7-222.8) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 1.4 | nc | (nc-nc) |  | Male | 65 | 61.7 | 105.4 | (81.3-134.3) |
| Female | 1 | 1.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 8 | 11.8 | 67.7 | (29.1-133.3) |  | Male | 1 | 4.7 | nc | (nc-nc) |
| Female | 5 | 6.3 | 79.4 | (25.6-185.4) |  | Female | 5 | 2.8 | 179.6 | (57.9-419.0) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 3 | 3.0 | nc | (nc-nc) |  | Male | 3 | 2.6 | nc | (nc-nc) |
| Female | 0 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 7 | 8.1 | 86.6 | (34.7-178.4) |  | Male | 7 | 5.3 | 133.1 | (53.3-274.3) |
| Female | 7 | 5.6 | 125.4 | (50.2-258.3) |  | Female | 11 | 15.2 | 72.2 | (36.0-129.3) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 7 | 7.3 | 95.3 | (38.2-196.4) |  |  |  |  |  |  |
| Female | 3 | 2.3 | nc | (nc-nc) |  | Female | 32 | 18.2 | 175.5 | (120.1-247.8) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 22 | 34.7 | 63.3 | (39.7-95.9) |  | Male | 252 | 257.5 | 97.9 | (86.1-110.7) |
| Female | 36 | 35.8 | 100.6 | (70.5-139.3) |  | Female | 296 | 264.0 | 112.1 | (99.7-125.7) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

143

# Holland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 3 | 3.0 | nc | (nc-nc) |  | Male | 2 | 2.1 | nc | (nc-nc) |
| Female | 2 | 0.8 | nc | (nc-nc) |  | Female | 0 | 1.3 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 2 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 1.8 | nc | (nc-nc) |
| Female | 9 | 10.6 | 84.6 | (38.6-160.7) |  | Female | 2 | 1.2 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 1.6 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 2 | 0.5 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 2 | 3.3 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 2.4 | nc | (nc-nc) |  | Female | 0 | 0.9 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 0.8 | nc | (nc-nc) |  | Male | 2 | 1.2 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.8 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.2 | nc | (nc-nc) |  | Male | 5 | 10.3 | 48.4 | (15.6-113.1) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 3 | 2.0 | nc | (nc-nc) |  | Male | 1 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.8 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 2 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 1.2 | nc | (nc-nc) |  | Male | 1 | 0.9 | nc | (nc-nc) |
| Female | 3 | 0.7 | nc | (nc-nc) |  | Female | 4 | 2.2 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 1.2 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 3 | 2.4 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 6 | 5.7 | 105.6 | (38.6-229.9) |  | Male | 35 | 41.4 | 84.6 | (58.9-117.7) |
| Female | 6 | 4.3 | 139.4 | (50.9-303.4) |  | Female | 35 | 33.3 | 105.0 | (73.1-146.0) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

144

# Holliston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 22 | 14.7 | 150.1 | (94.0-227.3) |  | Male | 11 | 9.8 | 112.4 | (56.0-201.1) |
| Female | 2 | 5.1 | nc | (nc-nc) |  | Female | 12 | 7.7 | 155.7 | (80.4-272.0) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 6 | 2.9 | 204.0 | (74.5-444.1) |  | Male | 6 | 3.1 | 191.1 | (69.8-416.1) |
| Female | 3 | 2.5 | nc | (nc-nc) |  | Female | 0 | 2.4 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 12 | 8.7 | 138.6 | (71.5-242.0) |
| Female | 68 | 64.0 | 106.3 | (82.5-134.7) |  | Female | 8 | 7.2 | 110.4 | (47.5-217.5) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 6 | 7.8 | 77.3 | (28.2-168.3) |
| Female | 2 | 2.2 | nc | (nc-nc) |  | Female | 5 | 3.3 | 149.7 | (48.2-349.4) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 15 | 16.1 | 93.0 | (52.0-153.5) |  |  |  |  |  |  |
| Female | 14 | 15.1 | 92.7 | (50.6-155.5) |  | Female | 4 | 5.4 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 4 | 3.9 | nc | (nc-nc) |  | Male | 5 | 5.6 | 88.5 | (28.5-206.5) |
| Female | 2 | 1.0 | nc | (nc-nc) |  | Female | 4 | 5.3 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 1.1 | nc | (nc-nc) |  | Male | 49 | 49.0 | 100.0 | (74.0-132.3) |
| Female | 0 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 12 | 9.3 | 129.3 | (66.8-225.9) |  | Male | 0 | 3.6 | nc | (nc-nc) |
| Female | 5 | 4.9 | 101.7 | (32.8-237.4) |  | Female | 1 | 2.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 2.3 | nc | (nc-nc) |  | Male | 4 | 2.0 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 8 | 6.1 | 131.7 | (56.7-259.5) |  | Male | 3 | 4.2 | nc | (nc-nc) |
| Female | 4 | 4.3 | nc | (nc-nc) |  | Female | 14 | 12.3 | 113.9 | (62.2-191.2) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 5.6 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 4 | 1.8 | nc | (nc-nc) |  | Female | 20 | 14.5 | 138.2 | (84.4-213.4) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 19 | 26.1 | 72.8 | (43.8-113.7) |  | Male | 203 | 197.3 | 102.9 | (89.2-118.0) |
| Female | 19 | 27.0 | 70.3 | (42.3-109.7) |  | Female | 205 | 205.3 | 99.9 | (86.7-114.5) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

145

# Holyoke

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 29 | 39.2 | 74.0 | (49.5-106.2) |  | Male | 13 | 24.7 | 52.7 | (28.0-90.1) |
| Female | 10 | 15.6 | 64.2 | (30.7-118.0) |  | Female | 13 | 21.2 | 61.5 | (32.7-105.1) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 8 | 7.6 | 105.6 | (45.5-208.0) |  | Male | 3 | 7.7 | nc | (nc-nc) |
| Female | 5 | 7.0 | 71.8 | (23.1-167.6) |  | Female | 4 | 7.0 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 1.3 | nc | (nc-nc) |  | Male | 17 | 22.1 | 77.0 | (44.8-123.3) |
| Female | 136 | 162.6 | 83.6 | (70.2-98.9) |  | Female | 19 | 20.8 | 91.4 | (55.0-142.8) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 21 | 17.4 | 120.7 | (74.7-184.6) |
| Female | 6 | 5.5 | 109.5 | (40.0-238.4) |  | Female | 10 | 9.1 | 110.0 | (52.7-202.3) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 40 | 40.9 | 97.9 | (69.9-133.3) |  |  |  |  |  |  |
| Female | 43 | 44.9 | 95.8 | (69.3-129.0) |  | Female | 14 | 14.3 | 97.8 | (53.4-164.2) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 5 | 9.3 | 53.9 | (17.4-125.9) |  | Male | 14 | 14.1 | 99.2 | (54.2-166.5) |
| Female | 0 | 3.0 | nc | (nc-nc) |  | Female | 20 | 16.4 | 121.9 | (74.4-188.2) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 5 | 3.1 | 163.5 | (52.7-381.5) |  | Male | 96 | 103.6 | 92.6 | (75.0-113.1) |
| Female | 6 | 2.9 | 206.6 | (75.4-449.6) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 24 | 21.3 | 112.9 | (72.3-168.0) |  | Male | 8 | 9.0 | 88.9 | (38.3-175.3) |
| Female | 12 | 13.3 | 90.1 | (46.5-157.3) |  | Female | 9 | 6.3 | 143.0 | (65.2-271.4) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 9 | 5.3 | 169.7 | (77.4-322.1) |  | Male | 3 | 5.8 | nc | (nc-nc) |
| Female | 3 | 1.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 10 | 16.3 | 61.3 | (29.4-112.8) |  | Male | 1 | 9.7 | nc | (nc-nc) |
| Female | 11 | 12.8 | 85.6 | (42.7-153.2) |  | Female | 27 | 31.3 | 86.4 | (56.9-125.7) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 19 | 12.9 | 147.1 | (88.5-229.8) |  |  |  |  |  |  |
| Female | 4 | 5.0 | nc | (nc-nc) |  | Female | 42 | 35.6 | 118.0 | (85.1-159.5) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 69 | 65.7 | 105.0 | (81.7-132.9) |  | Male | 444 | 478.1 | 92.9 | (84.4-101.9) |
| Female | 73 | 79.4 | 92.0 | (72.1-115.7) |  | Female | 523 | 563.1 | 92.9 | (85.1-101.2) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

146

# Hopedale

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 7 | 6.2 | 113.4 | (45.4-233.7) |  | Male | 2 | 3.8 | nc | (nc-nc) |
| Female | 3 | 2.4 | nc | (nc-nc) |  | Female | 4 | 3.3 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 1.1 | nc | (nc-nc) |  | Male | 0 | 1.2 | nc | (nc-nc) |
| Female | 0 | 1.1 | nc | (nc-nc) |  | Female | 2 | 1.1 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 3 | 3.4 | nc | (nc-nc) |
| Female | 27 | 26.1 | 103.3 | (68.1-150.4) |  | Female | 1 | 3.2 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 3 | 2.7 | nc | (nc-nc) |
| Female | 1 | 0.9 | nc | (nc-nc) |  | Female | 1 | 1.4 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 7 | 6.7 | 104.9 | (42.0-216.2) |  |  |  |  |  |  |
| Female | 9 | 7.1 | 127.3 | (58.1-241.6) |  | Female | 1 | 2.2 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 1.4 | nc | (nc-nc) |  | Male | 2 | 2.2 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 1 | 2.5 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 22 | 15.7 | 140.0 | (87.7-212.0) |
| Female | 1 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 2 | 3.3 | nc | (nc-nc) |  | Male | 3 | 1.4 | nc | (nc-nc) |
| Female | 2 | 2.1 | nc | (nc-nc) |  | Female | 1 | 1.0 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 0.8 | nc | (nc-nc) |  | Male | 1 | 0.9 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 2.5 | nc | (nc-nc) |  | Male | 2 | 1.5 | nc | (nc-nc) |
| Female | 1 | 2.0 | nc | (nc-nc) |  | Female | 7 | 5.0 | 139.4 | (55.9-287.3) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 3 | 2.0 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.8 | nc | (nc-nc) |  | Female | 7 | 5.6 | 124.6 | (49.9-256.7) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 16 | 9.6 | 166.6 | (95.1-270.5) |  | Male | 86 | 73.7 | 116.7 | (93.4-144.2) |
| Female | 13 | 11.9 | 109.0 | (58.0-186.3) |  | Female | 89 | 88.3 | 100.8 | (80.9-124.0) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

147

# Hopkinton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 14 | 12.2 | 114.8 | (62.7-192.7) |  | Male | 9 | 8.8 | 102.0 | (46.5-193.6) |
| Female | 11 | 4.6 | 240.3 | (119.8-430.0) |  | Female | 10 | 7.9 | 126.6 | (60.6-232.9) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 4 | 2.9 | nc | (nc-nc) |  | Male | 1 | 2.8 | nc | (nc-nc) |
| Female | 4 | 2.6 | nc | (nc-nc) |  | Female | 0 | 2.3 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.5 | nc | (nc-nc) |  | Male | 7 | 7.8 | 89.3 | (35.8-183.9) |
| Female | 67 | 65.1 | 102.9 | (79.8-130.7) |  | Female | 5 | 7.0 | 71.3 | (23.0-166.5) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 10 | 7.2 | 138.5 | (66.3-254.7) |
| Female | 4 | 2.5 | nc | (nc-nc) |  | Female | 2 | 3.2 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 18 | 14.6 | 123.1 | (72.9-194.5) |  |  |  |  |  |  |
| Female | 12 | 14.5 | 82.9 | (42.8-144.8) |  | Female | 4 | 5.3 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 3.4 | nc | (nc-nc) |  | Male | 4 | 4.8 | nc | (nc-nc) |
| Female | 1 | 0.9 | nc | (nc-nc) |  | Female | 8 | 4.8 | 168.2 | (72.4-331.5) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 1.1 | nc | (nc-nc) |  | Male | 59 | 41.7 | 141.6 | (107.8-182.7) |
| Female | 3 | 1.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 3 | 8.6 | nc | (nc-nc) |  | Male | 2 | 3.1 | nc | (nc-nc) |
| Female | 1 | 4.8 | nc | (nc-nc) |  | Female | 1 | 2.0 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 2.0 | nc | (nc-nc) |  | Male | 4 | 2.4 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 5.5 | nc | (nc-nc) |  | Male | 9 | 4.4 | 205.6 | (93.8-390.2) |
| Female | 1 | 4.2 | nc | (nc-nc) |  | Female | 13 | 13.9 | 93.2 | (49.6-159.4) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 3 | 5.1 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 1.6 | nc | (nc-nc) |  | Female | 10 | 14.0 | 71.6 | (34.3-131.7) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 14 | 21.9 | 63.8 | (34.9-107.1) |  | Male | 177 | 174.2 | 101.6 | (87.2-117.7) |
| Female | 23 | 24.6 | 93.7 | (59.4-140.6) |  | Female | 188 | 202.0 | 93.1 | (80.2-107.4) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

148

# Hubbardston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 3 | 4.5 | nc | (nc-nc) |  | Male | 1 | 3.0 | nc | (nc-nc) |
| Female | 1 | 1.2 | nc | (nc-nc) |  | Female | 1 | 2.2 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 0.9 | nc | (nc-nc) |  | Male | 1 | 1.0 | nc | (nc-nc) |
| Female | 2 | 0.7 | nc | (nc-nc) |  | Female | 2 | 0.6 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 5 | 2.7 | 185.3 | (59.7-432.5) |
| Female | 13 | 18.6 | 70.0 | (37.2-119.6) |  | Female | 2 | 2.0 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 2.4 | nc | (nc-nc) |
| Female | 1 | 0.7 | nc | (nc-nc) |  | Female | 5 | 0.9 | 547.4 | (176.4-1277.5) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 0 | 5.1 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 4 | 3.9 | nc | (nc-nc) |  | Female | 3 | 1.5 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 1.2 | nc | (nc-nc) |  | Male | 1 | 1.7 | nc | (nc-nc) |
| Female | 1 | 0.3 | nc | (nc-nc) |  | Female | 2 | 1.3 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 13 | 14.2 | 91.8 | (48.9-157.1) |
| Female | 1 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 3 | 2.8 | nc | (nc-nc) |  | Male | 2 | 1.1 | nc | (nc-nc) |
| Female | 2 | 1.4 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  | Male | 1 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 2 | 1.9 | nc | (nc-nc) |  | Male | 1 | 1.3 | nc | (nc-nc) |
| Female | 0 | 1.1 | nc | (nc-nc) |  | Female | 5 | 3.9 | 129.0 | (41.6-301.1) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 1.7 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 3 | 4.2 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 6 | 7.8 | 77.0 | (28.1-167.5) |  | Male | 46 | 59.8 | 76.9 | (56.3-102.6) |
| Female | 9 | 6.9 | 130.9 | (59.7-248.4) |  | Female | 61 | 56.7 | 107.6 | (82.3-138.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

149

# Hudson

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 21 | 21.5 | 97.8 | (60.5-149.4) |  | Male | 13 | 14.0 | 92.9 | (49.4-158.9) |
| Female | 8 | 8.4 | 95.8 | (41.2-188.7) |  | Female | 7 | 11.5 | 60.6 | (24.3-124.9) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 6 | 4.2 | 142.7 | (52.1-310.7) |  | Male | 4 | 4.5 | nc | (nc-nc) |
| Female | 5 | 3.7 | 133.4 | (43.0-311.2) |  | Female | 4 | 3.9 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 2 | 0.8 | nc | (nc-nc) |  | Male | 6 | 12.3 | 48.7 | (17.8-105.9) |
| Female | 96 | 95.9 | 100.1 | (81.1-122.3) |  | Female | 10 | 11.4 | 87.8 | (42.0-161.5) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 14 | 10.5 | 132.8 | (72.6-222.9) |
| Female | 2 | 3.1 | nc | (nc-nc) |  | Female | 6 | 5.1 | 117.4 | (42.9-255.5) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 26 | 22.6 | 115.3 | (75.3-168.9) |  |  |  |  |  |  |
| Female | 34 | 23.1 | 147.0 | (101.8-205.4) |  | Female | 9 | 8.1 | 111.1 | (50.7-211.0) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 5.6 | nc | (nc-nc) |  | Male | 3 | 8.1 | nc | (nc-nc) |
| Female | 0 | 1.7 | nc | (nc-nc) |  | Female | 4 | 8.6 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 1.6 | nc | (nc-nc) |  | Male | 66 | 69.0 | 95.7 | (74.0-121.8) |
| Female | 2 | 1.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 11 | 13.0 | 84.7 | (42.2-151.5) |  | Male | 2 | 5.1 | nc | (nc-nc) |
| Female | 9 | 7.6 | 117.7 | (53.7-223.4) |  | Female | 6 | 3.3 | 183.1 | (66.9-398.7) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 3.3 | nc | (nc-nc) |  | Male | 2 | 3.0 | nc | (nc-nc) |
| Female | 2 | 1.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 7 | 8.7 | 80.4 | (32.2-165.7) |  | Male | 7 | 5.8 | 121.4 | (48.7-250.2) |
| Female | 2 | 6.6 | nc | (nc-nc) |  | Female | 29 | 17.4 | 166.9 | (111.8-239.8) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 4 | 7.7 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 3 | 2.8 | nc | (nc-nc) |  | Female | 23 | 22.0 | 104.7 | (66.4-157.2) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 33 | 39.0 | 84.6 | (58.2-118.8) |  | Male | 256 | 281.3 | 91.0 | (80.2-102.9) |
| Female | 35 | 45.6 | 76.8 | (53.5-106.8) |  | Female | 320 | 316.4 | 101.1 | (90.4-112.8) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

150

# Hull

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 15 | 15.3 | 98.1 | (54.9-161.9) |  | Male | 14 | 9.6 | 145.7 | (79.6-244.6) |
| Female | 8 | 5.9 | 136.6 | (58.8-269.2) |  | Female | 14 | 7.7 | 181.1 | (98.9-303.8) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 3 | 2.6 | nc | (nc-nc) |  | Male | 4 | 3.2 | nc | (nc-nc) |
| Female | 4 | 2.4 | nc | (nc-nc) |  | Female | 2 | 2.7 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.5 | nc | (nc-nc) |  | Male | 3 | 8.4 | nc | (nc-nc) |
| Female | 61 | 65.3 | 93.4 | (71.5-120.0) |  | Female | 11 | 7.9 | 138.6 | (69.1-247.9) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 9 | 7.3 | 123.8 | (56.5-235.1) |
| Female | 2 | 1.9 | nc | (nc-nc) |  | Female | 5 | 3.6 | 140.8 | (45.4-328.6) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 17 | 15.3 | 110.8 | (64.5-177.5) |  |  |  |  |  |  |
| Female | 17 | 15.9 | 107.1 | (62.3-171.4) |  | Female | 5 | 5.6 | 88.9 | (28.6-207.4) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 4 | 4.0 | nc | (nc-nc) |  | Male | 7 | 5.7 | 122.7 | (49.1-252.8) |
| Female | 0 | 1.2 | nc | (nc-nc) |  | Female | 8 | 6.0 | 134.1 | (57.8-264.3) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 4 | 0.8 | nc | (nc-nc) |  | Male | 36 | 49.2 | 73.2 | (51.3-101.4) |
| Female | 1 | 0.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 13 | 8.7 | 148.7 | (79.1-254.3) |  | Male | 3 | 3.6 | nc | (nc-nc) |
| Female | 5 | 5.3 | 94.9 | (30.6-221.5) |  | Female | 1 | 2.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 3 | 2.4 | nc | (nc-nc) |  | Male | 4 | 1.3 | nc | (nc-nc) |
| Female | 4 | 0.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 4 | 5.8 | nc | (nc-nc) |  | Male | 3 | 3.4 | nc | (nc-nc) |
| Female | 2 | 4.4 | nc | (nc-nc) |  | Female | 7 | 10.6 | 65.9 | (26.4-135.8) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 11 | 5.7 | 194.2 | (96.8-347.6) |  |  |  |  |  |  |
| Female | 0 | 2.0 | nc | (nc-nc) |  | Female | 20 | 15.7 | 127.5 | (77.8-196.9) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 21 | 27.8 | 75.5 | (46.7-115.4) |  | Male | 193 | 195.3 | 98.8 | (85.4-113.8) |
| Female | 36 | 31.9 | 112.7 | (78.9-156.0) |  | Female | 225 | 216.4 | 104.0 | (90.8-118.5) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

151

# Huntington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 1 | 2.4 | nc | (nc-nc) |  | Male | 2 | 1.6 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 1 | 1.1 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 0.5 | nc | (nc-nc) |  | Male | 1 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 2 | 1.4 | nc | (nc-nc) |
| Female | 10 | 9.5 | 104.9 | (50.2-192.9) |  | Female | 4 | 1.0 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 1.3 | nc | (nc-nc) |
| Female | 1 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 3 | 2.5 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 3 | 2.0 | nc | (nc-nc) |  | Female | 2 | 0.8 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 0.7 | nc | (nc-nc) |  | Male | 0 | 0.9 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.2 | nc | (nc-nc) |  | Male | 4 | 8.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 4 | 1.5 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 1 | 0.7 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 3 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 1.0 | nc | (nc-nc) |  | Male | 0 | 0.7 | nc | (nc-nc) |
| Female | 1 | 0.6 | nc | (nc-nc) |  | Female | 2 | 1.8 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 1 | 2.3 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 7 | 4.3 | 162.0 | (64.9-333.9) |  | Male | 37 | 32.1 | 115.3 | (81.2-158.9) |
| Female | 5 | 4.1 | 122.0 | (39.3-284.7) |  | Female | 33 | 29.8 | 110.9 | (76.3-155.7) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

152

# Ipswich

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 20 | 17.5 | 114.1 | (69.7-176.3) |  | Male | 20 | 11.4 | 175.9 | (107.4-271.7) |
| Female | 10 | 6.8 | 146.6 | (70.2-269.6) |  | Female | 9 | 8.9 | 101.0 | (46.1-191.8) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 3 | 3.2 | nc | (nc-nc) |  | Male | 1 | 3.7 | nc | (nc-nc) |
| Female | 2 | 2.8 | nc | (nc-nc) |  | Female | 1 | 3.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 15 | 10.0 | 149.8 | (83.8-247.2) |
| Female | 91 | 73.0 | 124.6 | (100.3-153.0) |  | Female | 11 | 9.2 | 119.6 | (59.6-214.1) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 7 | 8.8 | 79.7 | (31.9-164.2) |
| Female | 3 | 2.2 | nc | (nc-nc) |  | Female | 4 | 4.0 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 17 | 18.6 | 91.4 | (53.2-146.4) |  |  |  |  |  |  |
| Female | 15 | 19.3 | 77.6 | (43.4-127.9) |  | Female | 3 | 6.3 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 9 | 4.6 | 196.5 | (89.7-373.1) |  | Male | 7 | 6.6 | 105.4 | (42.2-217.2) |
| Female | 2 | 1.3 | nc | (nc-nc) |  | Female | 5 | 7.2 | 69.6 | (22.4-162.4) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 1.1 | nc | (nc-nc) |  | Male | 62 | 56.7 | 109.3 | (83.8-140.1) |
| Female | 2 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 5 | 10.6 | 47.4 | (15.3-110.5) |  | Male | 1 | 4.2 | nc | (nc-nc) |
| Female | 7 | 5.8 | 119.7 | (48.0-246.6) |  | Female | 5 | 2.7 | 183.3 | (59.1-427.9) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 2.7 | nc | (nc-nc) |  | Male | 5 | 2.0 | 247.1 | (79.6-576.7) |
| Female | 0 | 0.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 5 | 6.9 | 72.3 | (23.3-168.8) |  | Male | 3 | 4.5 | nc | (nc-nc) |
| Female | 2 | 5.2 | nc | (nc-nc) |  | Female | 15 | 11.9 | 125.6 | (70.3-207.3) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 6 | 6.5 | 93.0 | (34.0-202.5) |  |  |  |  |  |  |
| Female | 2 | 2.3 | nc | (nc-nc) |  | Female | 15 | 17.0 | 88.4 | (49.5-145.9) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 21 | 31.4 | 66.8 | (41.4-102.2) |  | Male | 235 | 229.1 | 102.6 | (89.9-116.6) |
| Female | 25 | 35.0 | 71.5 | (46.2-105.5) |  | Female | 246 | 246.2 | 99.9 | (87.8-113.2) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

153

# Kingston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 14 | 14.3 | 97.7 | (53.4-164.0) |  | Male | 20 | 9.1 | 218.8 | (133.6-337.9) |
| Female | 6 | 5.6 | 108.0 | (39.4-235.1) |  | Female | 12 | 7.6 | 156.9 | (81.0-274.1) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 2.6 | nc | (nc-nc) |  | Male | 4 | 2.9 | nc | (nc-nc) |
| Female | 6 | 2.5 | 244.0 | (89.1-531.1) |  | Female | 2 | 2.5 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 8 | 8.1 | 98.9 | (42.6-194.9) |
| Female | 54 | 60.9 | 88.6 | (66.6-115.7) |  | Female | 6 | 7.6 | 79.4 | (29.0-172.7) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 4 | 6.7 | nc | (nc-nc) |
| Female | 5 | 2.1 | 235.3 | (75.8-549.2) |  | Female | 3 | 3.3 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 12 | 15.1 | 79.6 | (41.1-139.1) |  |  |  |  |  |  |
| Female | 9 | 16.4 | 54.8 | (25.0-104.0) |  | Female | 2 | 5.2 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 3.5 | nc | (nc-nc) |  | Male | 8 | 5.3 | 151.0 | (65.0-297.6) |
| Female | 4 | 1.1 | nc | (nc-nc) |  | Female | 9 | 5.9 | 153.2 | (69.9-290.9) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.9 | nc | (nc-nc) |  | Male | 44 | 40.9 | 107.6 | (78.2-144.5) |
| Female | 2 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 10 | 8.1 | 123.8 | (59.3-227.6) |  | Male | 3 | 3.3 | nc | (nc-nc) |
| Female | 2 | 4.8 | nc | (nc-nc) |  | Female | 1 | 2.3 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 2.1 | nc | (nc-nc) |  | Male | 4 | 1.7 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 9 | 5.7 | 157.5 | (71.9-299.0) |  | Male | 6 | 3.5 | 169.1 | (61.7-368.0) |
| Female | 3 | 4.5 | nc | (nc-nc) |  | Female | 12 | 11.5 | 104.5 | (53.9-182.5) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 4 | 5.0 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 1.8 | nc | (nc-nc) |  | Female | 16 | 13.1 | 122.4 | (69.9-198.8) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 29 | 24.7 | 117.6 | (78.7-168.9) |  | Male | 198 | 178.8 | 110.8 | (95.9-127.3) |
| Female | 28 | 28.1 | 99.7 | (66.2-144.1) |  | Female | 205 | 205.2 | 99.9 | (86.7-114.5) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

154

# Lakeville

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 15 | 12.1 | 124.0 | (69.4-204.6) |  | Male | 9 | 8.2 | 110.0 | (50.2-208.8) |
| Female | 5 | 3.9 | 129.0 | (41.6-301.0) |  | Female | 5 | 6.1 | 82.2 | (26.5-191.8) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 4 | 2.4 | nc | (nc-nc) |  | Male | 3 | 2.6 | nc | (nc-nc) |
| Female | 2 | 2.0 | nc | (nc-nc) |  | Female | 2 | 1.9 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 4 | 7.2 | nc | (nc-nc) |
| Female | 47 | 51.6 | 91.1 | (67.0-121.2) |  | Female | 5 | 5.7 | 87.3 | (28.1-203.8) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 6 | 6.6 | 91.5 | (33.4-199.1) |
| Female | 1 | 1.7 | nc | (nc-nc) |  | Female | 2 | 2.6 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 9 | 13.3 | 67.9 | (31.0-128.9) |  |  |  |  |  |  |
| Female | 11 | 11.4 | 96.3 | (48.0-172.2) |  | Female | 3 | 4.3 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 4 | 3.3 | nc | (nc-nc) |  | Male | 2 | 4.7 | nc | (nc-nc) |
| Female | 0 | 0.8 | nc | (nc-nc) |  | Female | 4 | 4.0 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 0.9 | nc | (nc-nc) |  | Male | 38 | 41.6 | 91.4 | (64.7-125.4) |
| Female | 1 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 5 | 7.8 | 64.1 | (20.7-149.7) |  | Male | 2 | 3.0 | nc | (nc-nc) |
| Female | 2 | 3.9 | nc | (nc-nc) |  | Female | 1 | 1.6 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 1.9 | nc | (nc-nc) |  | Male | 2 | 1.6 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 3 | 5.0 | nc | (nc-nc) |  | Male | 5 | 3.5 | 142.4 | (45.9-332.4) |
| Female | 2 | 3.3 | nc | (nc-nc) |  | Female | 18 | 9.8 | 184.1 | (109.1-291.0) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 5 | 4.8 | 104.4 | (33.6-243.5) |  |  |  |  |  |  |
| Female | 3 | 1.4 | nc | (nc-nc) |  | Female | 13 | 12.0 | 108.1 | (57.5-184.9) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 15 | 22.0 | 68.1 | (38.1-112.4) |  | Male | 147 | 165.2 | 89.0 | (75.2-104.6) |
| Female | 20 | 21.1 | 95.0 | (58.0-146.7) |  | Female | 170 | 162.4 | 104.7 | (89.5-121.7) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

155

# Lancaster

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 7 | 9.3 | 75.2 | (30.1-154.9) |  | Male | 5 | 5.9 | 84.6 | (27.3-197.3) |
| Female | 6 | 2.5 | 238.4 | (87.1-518.9) |  | Female | 4 | 3.7 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 1.8 | nc | (nc-nc) |  | Male | 1 | 1.9 | nc | (nc-nc) |
| Female | 0 | 1.2 | nc | (nc-nc) |  | Female | 1 | 1.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.3 | nc | (nc-nc) |  | Male | 6 | 5.3 | 113.2 | (41.4-246.5) |
| Female | 31 | 30.4 | 102.0 | (69.3-144.8) |  | Female | 5 | 3.5 | 140.9 | (45.4-328.8) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 3 | 4.3 | nc | (nc-nc) |
| Female | 0 | 1.0 | nc | (nc-nc) |  | Female | 0 | 1.6 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 7 | 9.4 | 74.6 | (29.9-153.8) |  |  |  |  |  |  |
| Female | 6 | 7.3 | 81.8 | (29.9-178.0) |  | Female | 3 | 2.6 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 2.4 | nc | (nc-nc) |  | Male | 2 | 3.4 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 0 | 2.6 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  | Male | 28 | 28.7 | 97.7 | (64.9-141.1) |
| Female | 0 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 2 | 5.3 | nc | (nc-nc) |  | Male | 0 | 2.2 | nc | (nc-nc) |
| Female | 2 | 2.4 | nc | (nc-nc) |  | Female | 0 | 1.0 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 1.4 | nc | (nc-nc) |  | Male | 1 | 1.5 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 4 | 3.8 | nc | (nc-nc) |  | Male | 3 | 2.4 | nc | (nc-nc) |
| Female | 1 | 2.1 | nc | (nc-nc) |  | Female | 4 | 5.9 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 3.2 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 0.9 | nc | (nc-nc) |  | Female | 2 | 6.9 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 6 | 16.5 | 36.3 | (13.2-79.0) |  | Male | 85 | 119.1 | 71.4 | (57.0-88.3) |
| Female | 13 | 13.5 | 96.5 | (51.3-165.1) |  | Female | 87 | 99.3 | 87.6 | (70.2-108.1) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

156

# Lanesborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 2 | 2.7 | nc | (nc-nc) |  | Male | 4 | 1.9 | nc | (nc-nc) |
| Female | 2 | 1.3 | nc | (nc-nc) |  | Female | 3 | 1.8 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 1 | 0.6 | nc | (nc-nc) |
| Female | 1 | 0.6 | nc | (nc-nc) |  | Female | 0 | 0.6 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 5 | 1.7 | 292.5 | (94.3-682.6) |
| Female | 12 | 14.3 | 83.8 | (43.3-146.4) |  | Female | 1 | 1.7 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 2 | 1.7 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 0 | 0.8 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 1 | 3.1 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 3 | 3.7 | nc | (nc-nc) |  | Female | 0 | 1.2 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 0.8 | nc | (nc-nc) |  | Male | 1 | 1.1 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 3 | 1.3 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.2 | nc | (nc-nc) |  | Male | 11 | 10.8 | 101.4 | (50.5-181.4) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 1 | 1.9 | nc | (nc-nc) |  | Male | 1 | 0.7 | nc | (nc-nc) |
| Female | 2 | 1.1 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 0.5 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 2 | 1.2 | nc | (nc-nc) |  | Male | 0 | 0.9 | nc | (nc-nc) |
| Female | 3 | 1.0 | nc | (nc-nc) |  | Female | 4 | 2.5 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 1.2 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 0.4 | nc | (nc-nc) |  | Female | 2 | 3.2 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 8 | 5.3 | 151.2 | (65.1-298.0) |  | Male | 48 | 40.5 | 118.5 | (87.4-157.2) |
| Female | 4 | 6.6 | nc | (nc-nc) |  | Female | 42 | 47.5 | 88.5 | (63.8-119.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

157

# Lawrence

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 51 | 51.0 | 100.1 | (74.5-131.6) |  | Male | 6 | 35.9 | 16.7 | (6.1-36.4) |
| Female | 16 | 21.1 | 75.9 | (43.4-123.3) |  | Female | 9 | 34.3 | 26.2 | (12.0-49.8) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 9 | 12.8 | 70.3 | (32.1-133.4) |  | Male | 13 | 11.2 | 116.2 | (61.8-198.7) |
| Female | 7 | 12.0 | 58.5 | (23.5-120.6) |  | Female | 23 | 10.2 | 226.5 | (143.5-339.9) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 1.9 | nc | (nc-nc) |  | Male | 25 | 32.3 | 77.4 | (50.1-114.3) |
| Female | 190 | 268.5 | 70.8 | (61.1-81.6) |  | Female | 33 | 31.1 | 106.3 | (73.1-149.2) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 25 | 28.2 | 88.6 | (57.3-130.8) |
| Female | 17 | 10.0 | 170.8 | (99.4-273.5) |  | Female | 9 | 14.0 | 64.1 | (29.3-121.7) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 63 | 58.4 | 108.0 | (83.0-138.1) |  |  |  |  |  |  |
| Female | 42 | 63.9 | 65.7 | (47.3-88.8) |  | Female | 13 | 22.9 | 56.8 | (30.2-97.1) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 7 | 13.8 | 50.8 | (20.4-104.8) |  | Male | 17 | 19.7 | 86.2 | (50.2-138.0) |
| Female | 7 | 4.2 | 166.6 | (66.7-343.2) |  | Female | 13 | 22.1 | 58.9 | (31.4-100.8) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 4 | 5.9 | nc | (nc-nc) |  | Male | 198 | 165.9 | 119.4 | (103.3-137.2) |
| Female | 10 | 5.5 | 183.1 | (87.7-336.8) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 26 | 34.0 | 76.4 | (49.9-111.9) |  | Male | 16 | 12.6 | 126.8 | (72.4-205.9) |
| Female | 29 | 20.7 | 139.8 | (93.6-200.7) |  | Female | 14 | 9.0 | 155.9 | (85.2-261.6) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 12 | 8.0 | 149.2 | (77.0-260.6) |  | Male | 11 | 11.9 | 92.3 | (46.0-165.1) |
| Female | 2 | 2.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 21 | 24.2 | 86.7 | (53.7-132.6) |  | Male | 14 | 17.6 | 79.6 | (43.5-133.6) |
| Female | 21 | 19.5 | 107.5 | (66.5-164.3) |  | Female | 65 | 58.7 | 110.7 | (85.4-141.1) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 38 | 19.8 | 191.7 | (135.6-263.1) |  |  |  |  |  |  |
| Female | 16 | 7.4 | 215.6 | (123.2-350.2) |  | Female | 48 | 58.9 | 81.5 | (60.1-108.0) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 93 | 90.8 | 102.4 | (82.7-125.5) |  | Male | 710 | 712.2 | 99.7 | (92.5-107.3) |
| Female | 101 | 110.7 | 91.2 | (74.3-110.8) |  | Female | 740 | 875.4 | 84.5 | (78.6-90.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

158

# Lee

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 16 | 8.9 | 179.9 | (102.8-292.2) |  | Male | 4 | 5.3 | nc | (nc-nc) |
| Female | 1 | 3.0 | nc | (nc-nc) |  | Female | 5 | 3.9 | 129.8 | (41.8-303.0) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 1.4 | nc | (nc-nc) |  | Male | 1 | 1.7 | nc | (nc-nc) |
| Female | 2 | 1.3 | nc | (nc-nc) |  | Female | 0 | 1.4 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 1 | 4.6 | nc | (nc-nc) |
| Female | 30 | 31.8 | 94.3 | (63.6-134.6) |  | Female | 4 | 4.0 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 3 | 3.6 | nc | (nc-nc) |
| Female | 1 | 0.9 | nc | (nc-nc) |  | Female | 1 | 1.8 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 9 | 8.6 | 104.2 | (47.5-197.8) |  |  |  |  |  |  |
| Female | 11 | 8.1 | 135.5 | (67.5-242.4) |  | Female | 2 | 2.8 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 4 | 2.1 | nc | (nc-nc) |  | Male | 3 | 3.1 | nc | (nc-nc) |
| Female | 1 | 0.6 | nc | (nc-nc) |  | Female | 1 | 3.1 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.5 | nc | (nc-nc) |  | Male | 19 | 24.1 | 78.9 | (47.5-123.3) |
| Female | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 6 | 4.5 | 133.4 | (48.7-290.4) |  | Male | 0 | 2.0 | nc | (nc-nc) |
| Female | 3 | 2.6 | nc | (nc-nc) |  | Female | 5 | 1.2 | 429.7 | (138.5-1002.7) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 1.2 | nc | (nc-nc) |  | Male | 2 | 0.8 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 2 | 3.3 | nc | (nc-nc) |  | Male | 4 | 1.7 | nc | (nc-nc) |
| Female | 1 | 2.3 | nc | (nc-nc) |  | Female | 4 | 5.3 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 2.8 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 1.0 | nc | (nc-nc) |  | Female | 7 | 7.4 | 94.3 | (37.8-194.2) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 17 | 15.2 | 111.5 | (64.9-178.6) |  | Male | 105 | 104.4 | 100.5 | (82.2-121.7) |
| Female | 24 | 16.0 | 149.8 | (95.9-222.9) |  | Female | 110 | 107.7 | 102.1 | (83.9-123.1) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

159

# Leicester

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 12 | 12.5 | 95.8 | (49.4-167.3) |  | Male | 11 | 8.3 | 133.3 | (66.5-238.6) |
| Female | 4 | 5.1 | nc | (nc-nc) |  | Female | 12 | 6.8 | 176.5 | (91.1-308.4) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 2.5 | nc | (nc-nc) |  | Male | 3 | 2.7 | nc | (nc-nc) |
| Female | 2 | 2.2 | nc | (nc-nc) |  | Female | 2 | 2.3 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.5 | nc | (nc-nc) |  | Male | 2 | 7.3 | nc | (nc-nc) |
| Female | 39 | 56.5 | 69.0 | (49.1-94.3) |  | Female | 4 | 6.8 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 10 | 6.4 | 156.5 | (74.9-287.8) |
| Female | 2 | 1.7 | nc | (nc-nc) |  | Female | 3 | 3.0 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 7 | 13.3 | 52.6 | (21.1-108.4) |  |  |  |  |  |  |
| Female | 11 | 14.0 | 78.7 | (39.2-140.8) |  | Female | 6 | 4.9 | 122.4 | (44.7-266.4) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 6 | 3.3 | 179.2 | (65.4-390.1) |  | Male | 1 | 4.8 | nc | (nc-nc) |
| Female | 0 | 1.0 | nc | (nc-nc) |  | Female | 6 | 5.1 | 117.4 | (42.9-255.5) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.9 | nc | (nc-nc) |  | Male | 37 | 40.7 | 90.8 | (64.0-125.2) |
| Female | 1 | 0.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 6 | 7.6 | 78.8 | (28.8-171.5) |  | Male | 1 | 3.0 | nc | (nc-nc) |
| Female | 6 | 4.6 | 131.2 | (47.9-285.5) |  | Female | 0 | 1.9 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 3 | 2.0 | nc | (nc-nc) |  | Male | 1 | 1.6 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 12 | 5.1 | 235.3 | (121.4-411.0) |  | Male | 6 | 3.3 | 180.1 | (65.8-392.1) |
| Female | 6 | 3.9 | 154.2 | (56.3-335.6) |  | Female | 4 | 9.7 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 4.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 2 | 1.7 | nc | (nc-nc) |  | Female | 12 | 13.0 | 92.5 | (47.7-161.5) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 10 | 22.6 | 44.3 | (21.2-81.4) |  | Male | 141 | 166.1 | 84.9 | (71.5-100.1) |
| Female | 21 | 27.7 | 75.9 | (47.0-116.1) |  | Female | 158 | 187.7 | 84.2 | (71.5-98.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

160

# Lenox

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 14 | 10.8 | 129.3 | (70.6-217.0) |  | Male | 7 | 5.9 | 119.4 | (47.8-246.1) |
| Female | 2 | 4.3 | nc | (nc-nc) |  | Female | 8 | 4.6 | 174.4 | (75.1-343.6) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 1.4 | nc | (nc-nc) |  | Male | 4 | 1.9 | nc | (nc-nc) |
| Female | 4 | 1.4 | nc | (nc-nc) |  | Female | 1 | 1.9 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 6 | 5.1 | 116.5 | (42.5-253.6) |
| Female | 35 | 36.4 | 96.1 | (66.9-133.7) |  | Female | 4 | 5.2 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 5 | 3.7 | 136.6 | (44.0-318.7) |
| Female | 0 | 0.9 | nc | (nc-nc) |  | Female | 2 | 2.2 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 14 | 10.0 | 140.6 | (76.8-235.9) |  |  |  |  |  |  |
| Female | 17 | 11.9 | 143.3 | (83.4-229.5) |  | Female | 5 | 3.3 | 152.0 | (49.0-354.6) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 2.3 | nc | (nc-nc) |  | Male | 4 | 3.6 | nc | (nc-nc) |
| Female | 0 | 0.8 | nc | (nc-nc) |  | Female | 5 | 4.7 | 107.5 | (34.6-250.8) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 24 | 25.2 | 95.4 | (61.1-141.9) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 5 | 4.6 | 109.5 | (35.3-255.6) |  | Male | 0 | 2.3 | nc | (nc-nc) |
| Female | 5 | 3.1 | 159.1 | (51.3-371.4) |  | Female | 0 | 1.7 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 1.3 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 2 | 3.7 | nc | (nc-nc) |  | Male | 0 | 1.6 | nc | (nc-nc) |
| Female | 3 | 3.1 | nc | (nc-nc) |  | Female | 2 | 4.7 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 2.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 2 | 1.3 | nc | (nc-nc) |  | Female | 5 | 8.2 | 61.2 | (19.7-142.8) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 11 | 17.2 | 64.0 | (31.9-114.4) |  | Male | 108 | 114.8 | 94.1 | (77.2-113.6) |
| Female | 16 | 21.0 | 76.3 | (43.6-123.9) |  | Female | 127 | 133.8 | 94.9 | (79.1-112.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

161

# Leominster

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 63 | 47.2 | 133.3 | (102.5-170.6) |  | Male | 22 | 29.7 | 74.0 | (46.4-112.1) |
| Female | 27 | 15.7 | 171.7 | (113.1-249.9) |  | Female | 19 | 22.7 | 83.9 | (50.5-131.0) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 6 | 8.5 | 70.2 | (25.6-152.8) |  | Male | 10 | 9.5 | 105.7 | (50.6-194.3) |
| Female | 9 | 7.3 | 122.7 | (56.0-232.9) |  | Female | 4 | 7.4 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 2 | 1.6 | nc | (nc-nc) |  | Male | 21 | 26.3 | 79.8 | (49.4-122.0) |
| Female | 169 | 179.3 | 94.3 | (80.6-109.6) |  | Female | 24 | 21.8 | 109.9 | (70.4-163.5) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 23 | 21.2 | 108.5 | (68.7-162.8) |
| Female | 7 | 6.1 | 114.8 | (46.0-236.5) |  | Female | 12 | 9.7 | 123.9 | (64.0-216.5) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 44 | 49.0 | 89.8 | (65.2-120.6) |  |  |  |  |  |  |
| Female | 37 | 46.0 | 80.4 | (56.6-110.8) |  | Female | 29 | 15.5 | 187.1 | (125.3-268.7) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 14 | 11.4 | 122.4 | (66.9-205.4) |  | Male | 18 | 17.1 | 105.1 | (62.3-166.2) |
| Female | 2 | 3.0 | nc | (nc-nc) |  | Female | 21 | 16.4 | 127.9 | (79.1-195.5) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 3.3 | nc | (nc-nc) |  | Male | 127 | 130.9 | 97.0 | (80.9-115.4) |
| Female | 3 | 3.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 34 | 25.9 | 131.1 | (90.8-183.2) |  | Male | 11 | 10.9 | 100.8 | (50.3-180.5) |
| Female | 15 | 14.3 | 105.1 | (58.8-173.4) |  | Female | 1 | 6.4 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 11 | 6.6 | 167.0 | (83.2-298.8) |  | Male | 4 | 6.3 | nc | (nc-nc) |
| Female | 0 | 2.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 18 | 18.7 | 96.4 | (57.1-152.4) |  | Male | 13 | 11.6 | 112.1 | (59.6-191.8) |
| Female | 14 | 13.1 | 107.1 | (58.5-179.7) |  | Female | 27 | 34.8 | 77.6 | (51.1-112.9) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 10 | 15.7 | 63.6 | (30.4-116.9) |  |  |  |  |  |  |
| Female | 5 | 5.3 | 94.9 | (30.6-221.4) |  | Female | 41 | 39.8 | 102.9 | (73.9-139.6) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 82 | 80.7 | 101.7 | (80.9-126.2) |  | Male | 579 | 580.2 | 99.8 | (91.8-108.3) |
| Female | 88 | 81.8 | 107.6 | (86.3-132.5) |  | Female | 602 | 599.3 | 100.5 | (92.6-108.8) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

162